UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934

 

For the quarterly period ended March 31, 2025

Commission File No. 000-22179

 

GUIDED THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

 

58-2029543

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

 

5835 Peachtree Corners East, Suite B

Peachtree Corners, Georgia 30092

(Address of principal executive offices) (Zip Code)

 

(770) 242-8723

(Registrant’s telephone number, including area code)     

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒     No ☐

 

Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

 

Large Accelerated filer

☐

Accelerated filer 

☐

Non-accelerated filer  

☒

Smaller reporting company 

☒

 

 

Emerging growth company 

☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13 (a) of the Exchange Act.  ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes ☐     No ☒ 

 

As of May 13, 2025, the registrant had 78,910,179 shares of Common Stock, $0.001 par value per share, outstanding.

 

 

 

  

PART I FINANCIAL INFORMATION

  

Page

 
Item 1.Financial Statements

3

 
 Unaudited Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024

3

 
 Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2025 and 2024

4

 
 Unaudited Condensed Consolidated Statements of Stockholders' Deficit for the Three Months Ended March 31, 2025 and 2024

5

 
 Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 2024

7

 
 Notes to Unaudited Condensed Consolidated Financial Statements

8

 
  

 

 
Item 2.Management s Discussion and Analysis of Financial Condition and Results of Operations

36

 
  

 

 
Item 3.Quantitative and Qualitative Disclosures About Market Risk

43

 
  

 

 
Item 4.Controls and Procedures

43

 
  

 

 

PART II OTHER INFORMATION

 

 

  
Item 1.

Legal Proceedings

44

 

 

 

 

 

Item 1A. 

Risk Factors

44

 

  

 

 
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds

44

 
    
Item 3.Defaults Upon Senior Securities

44

 
    
Item 4.Mine Safety Disclosures

44

 
    
Item 5.Other Information

44

 
    
Item 6.Exhibits

45

 
    
Signatures 

46

 
     

 

 
2

Table of Contents

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

(unaudited, in thousands)

 

 

 

 

 

 

 

 

 

March 31,

 

 

December 31,

 

 

 

2025

 

 

2024

 

ASSETS

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$115

 

 

$388

 

Accounts receivable, net of allowance for credit losses of $1 at March 31, 2025 and December 31, 2024

 

 

2

 

 

 

3

 

Inventory, net of reserves of $818 at March 31, 2025 and December 31, 2024

 

 

633

 

 

 

633

 

Other current assets

 

 

61

 

 

 

173

 

Total current assets

 

 

811

 

 

 

1,197

 

 

 

 

 

 

 

 

 

 

Non-Current Assets:

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

21

 

 

 

23

 

Operating lease right-of-use asset, net of amortization

 

 

118

 

 

 

141

 

Other assets

 

 

17

 

 

 

17

 

Total non-current assets

 

 

156

 

 

 

181

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$967

 

 

$1,378

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS DEFICIT

 

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$2,152

 

 

$2,094

 

Accounts payable, related parties

 

 

34

 

 

 

36

 

Accrued liabilities

 

 

1,062

 

 

 

1,011

 

Deferred revenue

 

 

670

 

 

 

849

 

Current portion of lease liability

 

 

110

 

 

 

106

 

Short-term notes payable due to related parties

 

 

24

 

 

 

70

 

Current portion of long-term debt, related parties

 

 

530

 

 

 

532

 

Short-term notes payable

 

 

48

 

 

 

92

 

Short-term convertible notes, net of discounts

 

 

73

 

 

 

117

 

Short-term convertible debt in default

 

 

1,130

 

 

 

1,130

 

Derivative liability at fair value

 

 

66

 

 

 

118

 

Total current liabilities

 

 

5,899

 

 

 

6,155

 

 

 

 

 

 

 

 

 

 

Long-Term Liabilities

 

 

 

 

 

 

 

 

Long-term lease liability

 

 

20

 

 

 

49

 

Long-term notes payable

 

 

41

 

 

 

47

 

Long-term convertible debt

 

 

35

 

 

 

14

 

Long-term debt, related parties

 

 

-

 

 

 

2

 

Total long-term liabilities

 

 

96

 

 

 

112

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

5,995

 

 

 

6,267

 

 

 

 

 

 

 

 

 

 

COMMITMENTS AND CONTINGENCIES (Note 6)

 

 

 

 

 

 

 

 

 

STOCKHOLDERS DEFICIT:

 

 

 

 

 

 

 

 

 

 

 

 

 

Series C convertible preferred stock, $0.001 par value; 9.0 shares authorized, nil and 0.3 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. Liquidation preference of nil and $286 at March 31, 2025 and December 31, 2024, respectively.

 

 

-

 

 

 

105

 

Series C1 convertible preferred stock, $0.001 par value; 20.3 shares authorized, 0.4 and 1.0 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. Liquidation preference of $374 and $1,049 at March 31, 2025 and December 31, 2024, respectively.

 

 

61

 

 

 

170

 

Series C2 convertible preferred stock, $0.001 par value; 5,000 shares authorized, nil and 2.7 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. Liquidation preference of nil and $2,700 at March 31, 2025 and December 31, 2024, respectively.

 

 

-

 

 

 

439

 

Series D convertible preferred stock, $0.001 par value; 6.0 shares authorized, 0.1 and 0.4 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. Liquidation preference of $88 and $438 at March 31, 2025 and December 31, 2024, respectively.

 

 

32

 

 

 

159

 

Series E convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.9 shares issued and outstanding as of March 31, 2025 and December 31, 2024. Liquidation preference of $883 at March 31, 2025 and December 31, 2024.

 

 

834

 

 

 

834

 

Series F convertible preferred stock, $0.001 par value; 1.5 shares authorized, 1.0 shares issued and outstanding as of March 31, 2025 and December 31, 2024. Liquidation preference of $981 at March 31, 2025 and December 31, 2024.

 

 

817

 

 

 

817

 

Series F-2 convertible preferred stock, $0.001 par value; 5.0 shares authorized, 0.5 shares issued and outstanding as of March 31, 2025 and December 31, 2024. Liquidation preference of $495 and $520 at March 31, 2025 and December 31, 2024, respectively.

 

 

452

 

 

 

475

 

Common stock, $0.001 par value; 500,000 shares authorized, 77,968 and 65,131 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.

 

 

3,464

 

 

 

3,452

 

Additional paid-in capital

 

 

143,616

 

 

 

142,501

 

Treasury stock at cost

 

 

(132)

 

 

(132)

Accumulated deficit

 

 

(154,172)

 

 

(153,709)

 

 

 

 

 

 

 

 

 

Total stockholders deficit

 

 

(5,028)

 

 

(4,889)

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT

 

$967

 

 

$1,378

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these condensed consolidated statements.

 

 
3

Table of Contents

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited, in thousands, except per share data)

 

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

Sales - devices and disposables

 

$-

 

 

$6

 

Cost of goods sold

 

 

-

 

 

 

2

 

Gross profit

 

 

-

 

 

 

4

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

 

74

 

 

 

54

 

Sales and marketing

 

 

73

 

 

 

73

 

General and administrative

 

 

267

 

 

 

236

 

Total operating expenses

 

 

414

 

 

 

363

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(414)

 

 

(359)

 

 

 

 

 

 

 

 

 

Other income (expenses):

 

 

 

 

 

 

 

 

Interest expense

 

 

(147)

 

 

(64)

Interest income

 

 

-

 

 

 

3

 

Change in fair value of derivative liability

 

 

52

 

 

 

-

 

Gain / (Loss) from extinguishment of debt

 

 

(16)

 

 

17

 

Other income

 

 

98

 

 

 

1

 

Total other income (expense)

 

 

(13)

 

 

(43)

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

 

(427)

 

 

(402)
Provision for income taxes

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(427)

 

 

(402)
Preferred stock dividends

 

 

(36)

 

 

(39)

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

 

$(463)

 

$(441)

 

 

 

 

 

 

 

 

 

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS

 

 

 

 

 

 

 

 

Basic

 

$(0.01)

 

$(0.01)

Diluted

 

$(0.01)

 

$(0.01)

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

 

Basic

 

 

68,291

 

 

 

54,750

 

Diluted

 

 

68,291

 

 

 

54,750

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
4

Table of Contents

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2025

(unaudited, in thousands)

 

 

 

Preferred Stock

 

 

Preferred Stock

 

 

Preferred Stock

 

 

Preferred Stock

 

 

 

Series C

 

 

Series C1

 

 

Series C2

 

 

Series D

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

Balance at December 31, 2024

 

 

-

 

 

$105

 

 

 

1

 

 

$170

 

 

 

2

 

 

$439

 

 

 

1

 

 

$159

 

Issuance of common stock and warrants in private placement offering

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series D preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series E preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series F-2 preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series C to common stock

 

 

-

 

 

 

(105)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series C1 to common stock

 

 

-

 

 

 

-

 

 

 

(1)

 

 

(109)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series C2 to common stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2)

 

 

(439)

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series D to common stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(1)

 

 

(127)
Conversion of Preferred Stock Series F-2 to common stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of debt to common stock and warrants

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Accrued preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Balance at March 31, 2025

 

 

-

 

 

$-

 

 

 

-

 

 

$61

 

 

 

-

 

 

$-

 

 

 

-

 

 

$32

 

 

 

 

Preferred Stock

 

 

Preferred Stock

 

 

Preferred Stock

 

 

 

Series E

 

 

Series F

 

 

Series F2

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

Balance at December 31, 2024

 

 

1

 

 

$834

 

 

 

1

 

 

$817

 

 

 

 

 

$475

 

Issuance of common stock and warrants in private placement offering

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series D preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series E preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series F-2 preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series C to common stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series C1 to common stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series C2 to common stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series D to common stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series F-2 to common stock

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(23)
Conversion of debt to common stock and warrants

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Accrued preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Balance at March 31, 2025

 

 

1

 

 

$834

 

 

 

1

 

 

$817

 

 

 

-

 

 

$452

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Paid-In

 

 

Treasury

 

 

Accumulated

 

 

 

 

 

Shares

 

 

Amount

 

 

 Capital

 

 

Stock

 

 

Deficit

 

 

Total

 

Balance at December 31, 2024

 

 

65,131

 

 

$3,452

 

 

$142,501

 

 

$(132)

 

$(153,709)

 

$(4,889)

Issuance of common stock and warrants in private placement offering

 

 

2,045

 

 

 

2

 

 

 

203

 

 

 

-

 

 

 

-

 

 

 

205

 

Issuance of common stock for payment of Series D preferred dividends

 

 

52

 

 

 

-

 

 

 

7

 

 

 

-

 

 

 

-

 

 

 

7

 

Issuance of common stock for payment of Series E preferred dividends

 

 

49

 

 

 

-

 

 

 

7

 

 

 

-

 

 

 

-

 

 

 

7

 

Issuance of common stock for payment of Series F-2 preferred dividends

 

 

7

 

 

 

-

 

 

 

1

 

 

 

-

 

 

 

-

 

 

 

1

 

Conversion of Preferred Stock Series C to common stock

 

 

2,259

 

 

 

2

 

 

 

103

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series C1 to common stock

 

 

1,350

 

 

 

1

 

 

 

108

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series C2 to common stock

 

 

5,400

 

 

 

5

 

 

 

434

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series D to common stock

 

 

1,050

 

 

 

1

 

 

 

126

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of Preferred Stock Series F-2 to common stock

 

 

100

 

 

 

-

 

 

 

23

 

 

 

-

 

 

 

-

 

 

 

-

 

Conversion of debt to common stock and warrants

 

 

525

 

 

 

1

 

 

 

84

 

 

 

-

 

 

 

-

 

 

 

85

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

19

 

 

 

-

 

 

 

-

 

 

 

19

 

Accrued preferred dividends

 

 

 

 

 

 

-

 

 

 

 

 

 

 

-

 

 

 

(36)

 

 

(36)

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(427)

 

 

(427)

Balance at March 31, 2025

 

 

77,968

 

 

$3,464

 

 

$143,616

 

 

$(132)

 

$(154,172)

 

$(5,028)

 

The accompanying notes are an integral part of these condensed consolidated statements.

 

 
5

Table of Contents

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS DEFICIT

FOR THE THREE MONTHS ENDED MARCH 31, 2024

(unaudited, in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred Stock

Series C

 

 

Preferred Stock

Series C1

 

 

Preferred Stock

Series C2

 

 

Preferred Stock

Series D

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

Balance at December 31, 2023

 

 

-

 

 

$105

 

 

 

1

 

 

$170

 

 

 

2

 

 

$439

 

 

 

1

 

 

$159

 

Issuance of common stock for payment of Series D preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series E preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series F preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series F-2 preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Settlement of previously accrued professional fees through common stock issuance

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Accrued preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Balance at March 31, 2024

 

 

-

 

 

$105

 

 

 

1

 

 

$170

 

 

 

2

 

 

$439

 

 

 

1

 

 

$159

 

 

 

 

Preferred Stock

 

 

Preferred Stock

 

 

Preferred Stock

 

 

 

Series E

 

 

Series F

 

 

Series F2

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

Balance at December 31, 2023

 

 

1

 

 

$834

 

 

 

1

 

 

$838

 

 

 

-

 

 

$475

 

Issuance of common stock for payment of Series D preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series E preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series F preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of Series F-2 preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Issuance of common stock for payment of interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Settlement of previously accrued professional fees through common stock issuance

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Accrued preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Balance at March 31, 2024

 

 

1

 

 

$834

 

 

 

1

 

 

$838

 

 

 

-

 

 

$475

 

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

Paid-In

 

 

 Treasury

 

 

Accumulated

 

 

 

 

 

 

Shares

 

 

Amount

 

 

 Capital

 

 

 Stock

 

 

Deficit

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2023

 

 

54,106

 

 

$3,441

 

 

$140,983

 

 

$(132)

 

$(151,118)

 

$(3,806)

Issuance of common stock for payment of Series D preferred dividends

 

 

54

 

 

 

-

 

 

 

9

 

 

 

-

 

 

 

-

 

 

 

9

 

Issuance of common stock for payment of Series E preferred dividends

 

 

52

 

 

 

-

 

 

 

8

 

 

 

-

 

 

 

-

 

 

 

8

 

Issuance of common stock for payment of Series F preferred dividends

 

 

445

 

 

 

-

 

 

 

54

 

 

 

-

 

 

 

-

 

 

 

54

 

Issuance of common stock for payment of Series F-2 preferred dividends

 

 

164

 

 

 

-

 

 

 

20

 

 

 

-

 

 

 

-

 

 

 

20

 

Issuance of common stock for payment of interest

 

 

393

 

 

 

-

 

 

 

57

 

 

 

-

 

 

 

-

 

 

 

57

 

Settlement of previously accrued professional fees through common stock issuance

 

 

400

 

 

 

-

 

 

 

57

 

 

 

-

 

 

 

-

 

 

 

57

 

Stock-based compensation

 

 

-

 

 

 

-

 

 

 

30

 

 

 

-

 

 

 

-

 

 

 

30

 

Accrued preferred dividends

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(39)

 

 

(39)

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(402)

 

 

(402)

Balance at March 31, 2024

 

 

55,614

 

 

$3,441

 

 

$141,218

 

 

$(132)

 

$(151,559)

 

$(4,012)

 

The accompanying notes are an integral part of these condensed consolidated statements.

 

 
6

Table of Contents

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited, in thousands)

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2025

 

 

2024

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$(427)

 

$(402)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation

 

 

2

 

 

 

2

 

Amortization of debt issuance costs and discounts

 

 

67

 

 

 

32

 

Stock based compensation

 

 

19

 

 

 

30

 

Change in fair value of derivatives

 

 

(52)

 

 

-

 

Amortization of lease right-of-use-asset

 

 

23

 

 

 

21

 

Loss (Gain) from extinguishment of debt

 

 

16

 

 

 

(17)

Other non-cash expenses (income)

 

 

7

 

 

 

-

 

Change in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

1

 

 

 

1

 

Inventory

 

 

-

 

 

 

-

 

Other current assets

 

 

111

 

 

 

8

 

Accounts payable and accrued liabilities

 

 

106

 

 

 

(78)

Lease liabilities

 

 

(25)

 

 

(21)

Deferred revenue

 

 

(179)

 

 

324

 

NET CASH USED IN OPERATING ACTIVITIES

 

 

(331)

 

 

(100)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from private placement offering

 

 

205

 

 

 

-

 

Payments made on notes payable

 

 

(147)

 

 

(46)

NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES

 

 

58

 

 

 

(46)

 

 

 

 

 

 

 

 

 

NET CHANGE IN CASH AND CASH EQUIVALENTS

 

 

(273)

 

 

(146)

 

 

 

 

 

 

 

 

 

Cash at beginning of period

 

 

388

 

 

 

591

 

 

 

 

 

 

 

 

 

 

CASH AT END OF PERIOD

 

$115

 

 

$445

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Cash paid for interest

 

$20

 

 

$12

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Dividends on preferred stock

 

$36

 

 

$39

 

Common stock issued for payment of interest

 

$-

 

 

$57

 

Common stock issued for payment of accrued dividends

 

$15

 

 

$91

 

Settlement of previously accrued professional fees through common stock issuance

 

$-

 

 

$57

 

Conversion of Preferred Stock Series C to common stock

 

$105

 

 

$-

 

Conversion of Preferred Stock Series C1 to common stock

 

$109

 

 

$-

 

Conversion of Preferred Stock Series C2 to common stock

 

$439

 

 

$-

 

Conversion of Preferred Stock Series D to common stock

 

$127

 

 

$-

 

Conversion of Preferred Stock Series F-2 to common stock

 

$23

 

 

$-

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 
7

Table of Contents

 

GUIDED THERAPEUTICS, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION

 

Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. The December 31, 2024 balances reported herein are derived from the audited consolidated financial statements for the year ended December 31, 2024. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

 

All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of March 31, 2025 and December 31, 2024, and the consolidated results of operations and cash flows for the three months ended March 31, 2025 and 2024 have been included.

 

The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of March 31 2025, it had an accumulated deficit of approximately $154.2 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete the development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development.

 

Going Concern

 

The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.

 

At March 31, 2025, the Company had negative working capital of approximately $5.1 million, accumulated deficit of $154.2 million, and incurred a net loss including preferred dividends of $0.5 million for the three months then ended. Stockholders’ deficit totaled approximately $5.0 million at March 31, 2025, primarily due to recurring net losses from operations.

 

 
8

Table of Contents

 

During the three months ended March 31, 2025, the Company received $0.2 million of proceeds from a private placement offering. The Company will need to continue to raise capital in order to provide funding for its operations and FDA/NMPA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.

 

2. SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the inventory valuation, valuation of share-based compensation and the valuation of the convertible note payable derivative liability. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to the Company’s financial statements.

 

Recently Issued Accounting Pronouncements Not Yet Adopted

 

In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. This guidance will be effective for the annual periods beginning the year ended December 31, 2025. This ASU will result in the required additional disclosures being included in the Company’s consolidated financial statements, once adopted.

 

In November 2024, the FASB issued ASU No. 2024-03 “Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” This ASU requires public business entities to disclose, for interim and annual reporting periods, additional information about certain income statement expense categories. The requirements are effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. Entities are permitted to apply either the prospective or retrospective transition methods. The Company is currently evaluating the impact that the adoption of this ASU will have on its consolidated financial statements.

 

A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements.

 

Cash Equivalents

 

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.

 

Concentrations of Credit Risk

 

The Company maintains a cash balance in a financial institution that is insured by the Federal Deposit Insurance Corporation up to certain federal limitations. At times, the Company’s cash balance exceeds these federal limitations. The amount in excess of insured limitations was nil and $137,770 as of March 31, 2025 and December 31, 2024, respectively.

 

 
9

Table of Contents

 

Inventory Valuation

 

All inventories are stated at the lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis.  Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. Inventories consisted of the following as of March 31, 2025 and December 31, 2024:

 

 

 

(in thousands)

 

 

 

March 31,

 

 

December 31,

 

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

Raw materials

 

$1,360

 

 

$1,362

 

Work-in-progress

 

 

48

 

 

 

46

 

Finished goods

 

 

43

 

 

 

43

 

Inventory reserve

 

 

(818)

 

 

(818)

 

 

 

 

 

 

 

 

 

Total inventory

 

$633

 

 

$633

 

 

The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.

 

Property and Equipment

 

Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Depreciation and amortization expense are included in general and administrative expense on the statements of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment consisted of the following as of March 31, 2025 and December 31, 2024:

 

 

 

(in thousands)

 

 

 

March 31,

 

 

December 31,

 

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

Equipment

 

$951

 

 

$951

 

Software

 

 

634

 

 

 

634

 

Furniture and fixtures

 

 

17

 

 

 

17

 

Leasehold improvements

 

 

12

 

 

 

12

 

 

 

 

 

 

 

 

 

 

Subtotal

 

 

1,614

 

 

 

1,614

 

Less accumulated depreciation

 

 

(1,593)

 

 

(1,591)

Property, equipment and leasehold improvements, net

 

$21

 

 

$23

 

 

Depreciation expense related to property and equipment for the three months ended March 31, 2025 and 2024 was not material.

 

Debt Issuance Costs

 

Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount.

 

Patent Costs (Principally Legal Fees)

 

Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs were not material for the three months ended March 31, 2025 and 2024.

 

 
10

Table of Contents

 

Leases

 

A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term.

 

Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities.

 

The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 6 – “Commitments and Contingencies.”

 

Accrued Liabilities

 

Accrued liabilities as of March 31, 2025 and December 31, 2024 are summarized as follows:

 

 

 

 

 

 

(in thousands)

 

 

 

March 31,

2025

 

 

December 31,

2024

 

 

 

 

 

 

 

 

Compensation

 

$445

 

 

$424

 

Professional fees

 

 

39

 

 

 

81

 

Interest

 

 

291

 

 

 

243

 

Vacation

 

 

31

 

 

 

26

 

Preferred dividends

 

 

250

 

 

 

227

 

Other accrued expenses

 

 

6

 

 

 

10

 

 

 

 

 

 

 

 

 

 

Total

 

$1,062

 

 

$1,011

 

 

Stock Subscription Payable

 

Cash received from investors for shares of common stock that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet.

 

 
11

Table of Contents

 

Revenue Recognition

 

ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. The application of the core principle in ASC 606 is carried out in five steps:

 

 

·

Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled.

 

 

 

 

·

Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract.

 

 

 

 

·

Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties.

 

 

 

 

·

Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted.

 

 

 

 

·

Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date.

 

The Company’s revenues do not require significant estimates or judgments and are recognized when control of the promised goods or services is transferred to the Company’s customers, which occurs at a point in time, most frequently upon shipment of the product or receipt of the product, depending on shipment terms. Revenue is measured as the amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company does not offer returns, discounts, loyalty programs or other sales incentive programs that are material to revenue recognition. The Company is not party to contracts that include multiple performance obligations or material variable consideration.

 

Contract Balances

 

The Company records deferred revenue when cash payments are received or due in advance of performance, including amounts billed or collected for which the related performance obligations have not been satisfied. Deferred revenue totaled $670,305, $848,917 and $424,225 as of March 31, 2025, December 31, 2024 and December 31, 2023, respectively.

 

Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The credit loss allowance was immaterial as of March 31, 2025 and December 31, 2024.

 

 
12

Table of Contents

 

Research and Development

 

Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.

 

Income Taxes

 

The provision for income taxes is determined in accordance with ASC 740, “Income Taxes”. The Company provides for income taxes based on enacted tax law and statutory tax rates at which items of income and expense are expected to be settled in our income tax return. Certain items of revenue and expense are reported for Federal income tax purposes in different periods than for financial reporting purposes, thereby resulting in deferred income taxes. Deferred taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

 

The Company has filed its 2024 federal and state corporate tax returns. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At March 31, 2025, the Company had approximately $62.8 million of net operating losses carryforward available, $2.9 million of which will expire on December 31, 2026. The remaining net operating loss will be eligible to be carried forward for tax purposes at federal and applicable state’s level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses.

 

The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations.

 

Warrants

 

The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes or binomial option pricing models.

 

Stock Based Compensation

 

The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “Compensation – Stock Compensation”, which requires fair value measurement on the grant date and recognition of compensation expense for all stock-based payment awards made to employees and directors. The Company determines the fair value of stock options using the Black-Scholes model. The fair value of restricted stock awards is based upon the quoted market price of the shares of common stock on the date of grant. The fair value of stock-based awards is expensed over the requisite service periods of the awards. The Company accounts for forfeitures of stock-based awards as they occur.

 

The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future.

 

During the three months ended March 31, 2025, the Company recognized $19,296 of expense for stock options. During the three months ended March 31, 2024, the Company recognized $14,837 of expense related to stock options and $15,466 of expense for warrants issued a consultant.

 

 
13

Table of Contents

 

Derivatives

 

The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

 

Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

 

Fair Value Measurements

 

ASC 820, “Fair Value Measurements and Disclosures,” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that should be determined based upon assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

 

 

·

Level 1: Quoted prices for identical assets or liabilities in active markets that the Company can access at the measurement date.

 

 

 

 

·

Level 2: Significant other observable inputs other than level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data.

 

 

 

 

·

Level 3: Significant unobservable inputs that reflect the Company’s judgment about the assumptions that market participants would use in pricing an asset or liability.

 

An asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

 

Assets and liabilities measured at fair value are based on one or more of the following three valuation techniques noted in ASC 820:

 

 

·

Market approach: Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

 

 

 

 

·

Cost approach: Amount that would be required to replace the service capacity of an asset (replacement cost).

 

 

 

 

·

Income approach: Techniques to convert future amounts to a single present value amount

 

The Company believes its valuation methods are appropriate and consistent with other market participants, however the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

 

 
14

Table of Contents

 

3. STOCKHOLDERS’ DEFICIT

 

Private Placement Offering

 

On March 18, 2025, the Company entered into a Securities Purchase Agreement (the “March Purchase Agreement”) with certain institutional investors, including John Imhoff and Michael James, members of the Company’s Board of Directors, for the purpose of raising $204,501 in gross proceeds for the Company. Pursuant to the terms of the March Purchase Agreement, the Company agreed to sell, in a private placement offering, an aggregate of 2,045,009 units, each unit consisting of one share of common stock and one warrant to purchase up to 2,045,009 shares of common stock (the “March Warrants”). The purchase price per unit was $0.10. The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share.

 

In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above. Additionally, the Company entered into an exchange agreement with Mr. James, whereby Mr. James agreed to exchange a $25,000 note payable and accrued interest of $1,295 for 262,945 units as described above. During the three months ended March 31, 2025, the Company recorded a loss on extinguishment of debt of $31,928 for the exchange agreements.

 

C-1 and C-2 Preferred Stock Exchanges

 

On March 3, 2025, the Company entered into exchange agreements with certain accredited investors, including Mark Faupel and John Imhoff, members of the Company’s board of directors, to exchange 675 shares of Series C-1 Preferred Stock and 2,700 shares of Series C-2 Preferred stock into 6,750,000 shares of common stock.

 

Common Stock

 

The Company has authorized 500,000,000 shares of common stock with $0.001 par value. As of March 31, 2025 and December 31, 2024, 77,967,594 and 65,130,623 shares of common stock were issued and outstanding, respectively.

 

During the three months ended March 31, 2025, the Company issued 12,836,971 shares of common stock, as summarized below:

 

 

 

Number of

Shares

 

 

 

 

 

 

Issurance of common stock in private placement offering

 

 

2,571,023

 

Issuance of common stock for payment of Series D preferred dividends

 

 

51,555

 

Issuance of common stock for payment of Series E preferred dividends

 

 

48,668

 

Issuance of common stock for payment of Series F-2 preferred dividends

 

 

7,035

 

Conversion of Preferred Series C stock to common stock

 

 

2,258,690

 

Conversion of Preferred Series C-1 stock to common stock

 

 

1,350,000

 

Conversion of Preferred Series C-2 stock to common stock

 

 

5,400,000

 

Conversion of Preferred Series D stock to common stock

 

 

1,050,000

 

Conversion of Preferred Series F-2 stock to common stock

 

 

100,000

 

Total common stock issued during the three months ended March 31, 2025

 

 

12,836,971

 

 

 

 

 

 

Summary table of common stock transactions:

 

 

 

 

Shares outstanding at December 31, 2024

 

 

65,130,623

 

Common shares issued during the three months ended March 31, 2025

 

 

12,836,971

 

Shares outstanding at March 31, 2025

 

 

77,967,594

 

 

 
15

Table of Contents

 

Preferred Stock

 

The Company has authorized 5,000,000 shares of preferred stock with a $0.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions.

 

Series C Convertible Preferred Stock

 

The board designated 9,000 shares of preferred stock as Series C Convertible Preferred Stock, (the “Series C Preferred Stock”). Pursuant to the Series C certificate of designations, shares of Series C Preferred Stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for the Company’s common stock. During the three months ended March 31, 2025, the Company issued 2,258,690 common shares to Mr. Imhoff for the conversion of his 286 Series C Convertible Preferred shares. At March 31, 2025 and December 31, 2024, there were nil and 286 shares outstanding, respectively.

 

Holders of the Series C Preferred Stock were entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. Unpaid accrued dividends were $120,120 as of March 31, 2025 and December 31, 2024.

 

Series C1 Convertible Preferred Stock

 

The board designated 20,250 shares of preferred stock as Series C1 Preferred Stock, of which 374.25 and 1,049.25 shares were issued and outstanding at March 31, 2025 and December 31, 2024, respectively. The C1 Convertible Preferred Stock has a conversion price of $0.50 per share.

 

The Series C1 Preferred Stock has terms that are substantially the same as the Series C Preferred Stock, except that the Series C1 Preferred Stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C Preferred Stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt.

 

Series C2 Convertible Preferred Stock

 

On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Convertible Preferred Stock, including the chairman of the Company’s board of directors, the former Chief Operating Officer (now the Chief Executive Officer) and a director of the Company pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Convertible Preferred Stock. In total, for 3,262.25 shares of Series C1 Convertible Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Convertible Preferred Stock. At March 31, 2025 and December 31, 2024, there were nil and 2,700 shares outstanding.

 

Series D Convertible Preferred Stock

 

The board designated 6,000 shares of preferred stock as Series D Preferred Stock, 88 and 438 of which remained outstanding as of March 31, 2025 and December 31, 2024, respectively. On January 8, 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series D Investors”) pursuant to all obligations under the Series D Certificate of Designation. The Series D Investors included the Chief Executive Officer, Chief Operating Officer (now the Chief Executive Officer) and a director of the Company. In total, for $763,000 the Company issued 763 shares of Series D Preferred Stock, 1,526,000 shares of common stock, 1,526,000 common stock warrants exercisable at $0.25, and 1,526,000 common stock warrants, exercisable at $0.75. Each Series D Preferred Stock is convertible into 3,000 shares of common stock. The Series D Preferred Stock have cumulative dividends at the rate per share of 10% per annum. Each share of Series D Preferred Stock has a par value of $0.001 per share and a stated value equal to $750.

 

 
16

Table of Contents

 

Each share of Series D Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series D Certificate of Designation (the “Series D Conversion Price”). The conversion of Series D Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series D Preferred. If the average of the VWAPs (as defined in the Series D Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series D Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series D Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.

 

During the three months ended March 31, 2025, the Company issued 900,000 common shares to Mr. Imhoff for the conversion of his 300 Series D Convertible Preferred shares. During the three months ended March 31, 2025, the Company issued 51,555 shares of common stock for payment of accrued Series D Preferred Stock dividends. As of March 31, 2025, and December 31, 2024, the Company had accrued dividends for the Series D Preferred Stock of $148 and $8,360, respectively.

 

Series E Convertible Preferred Stock

 

The Board designated 5,000 shares of preferred stock as Series E Preferred Stock, 883 of which remained outstanding as of March 31, 2025 and December 31, 2024. During year ended December 31, 2020, the Company entered into a Security Agreement with the Series E Investors (the “Series E Security Agreement”) pursuant to which all obligations under the Series E Certificate of Designation are secured by all of the Company’s assets and personal properties, with certain accredited investors. In total, for $1,736,000 the Company issued 1,736 shares of Series E Preferred Stock. Each Series E Preferred Stock is convertible into 4,000 common stock shares. The stated value and liquidation preference on the Series E Preferred Stock is $1,736.

 

Each share of Series E Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series E Certificate of Designation (the “Series E Conversion Price”). The conversion of Series E Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series E Preferred. If the average of the VWAPs (as defined in the Series E Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series E Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series E Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. Each share of Series E Preferred Stock has a par value of $0.001 per share and a stated value equal to $1,000, subject to the increase set forth in its Certificate of Designation.

 

Each holder of Series E Preferred Stock is entitled to receive cumulative dividends of 8% per annum, payable annually in cash or, at the option of the Company, shares of common stock.

 

During the three months ended March 31, 2025, the Company issued 48,668 shares of common stock for payment of accrued Series E Preferred Stock dividends. As of March 31, 2025 and December 31, 2024, the Company had accrued dividends of $39,932 and $30,272 for the Series E Preferred Stock, respectively.

 

Series F Convertible Preferred Stock

 

The Board designated 1,500 shares of preferred stock as Series F Preferred Stock, 981 of which remained outstanding as of March 31, 2025 and December 31, 2024. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F Investors”). In total, for $1,436,000 the Company issued 1,436 shares of Series F Preferred Stock. Each Series F Preferred Stock is convertible into 4,000 shares of common stock. The Series F Preferred Stock is entitled to cumulative dividends at the rate per share of 6% per annum. The stated value on the Series F Preferred Stock is $1,000.

 

 
17

Table of Contents

 

Each share of Series F Preferred Stock is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F Certificate of Designation (the “Series F Conversion Price”). The conversion of Series F Preferred Stock is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder. If the average of the VWAPs (as defined in the Series F Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F Preferred, for cash in an amount equal to aggregate stated value then outstanding plus accrued but unpaid dividends.

 

As of March 31, 2025 and December 31, 2024, the Company had accrued dividends for Series F preferred shares of $59,514 and $44,799, respectively.

 

Series F-2 Convertible Preferred Stock

 

The Company was oversubscribed for its Series F Preferred Stock, resulting in the requirement to file an additional Certificate of Designation for Series F-2 Preferred Stock with substantially the same terms as the Series F Preferred Stock. The Board designated 3,500 shares of preferred stock as Series F-2 Preferred Stock, 495 and 520 of which were issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors. In total, for $678,000 the Company issued 678 shares of Series F-2 Preferred Stock. In addition, the Company exchanged outstanding debt of $2,559,000 for 2,559 shares of Series F-2 Preferred Stock. Each Series F-2 Preferred share is convertible into 4,000 shares of common stock. The Series F-2 Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value on the Series F-2 Preferred Stock is $1,000.

 

Each share of Series F-2 Preferred Stock is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred Stock, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends.

 

During the three months ended March 31, 2025, the Company issued 7,035 shares of common stock for the payment of annual Series F-2 Preferred Stock dividends. As of March 31, 2025 and December 31, 2024, the Company had accrued dividends for Series F-2 preferred shares of $29,843 and $23,518, respectively.

 

Warrants

 

The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the three months ended March 31, 2025 and 2024:

 

 

 

Warrants

(Underlying

Shares)

 

 

Weighted-

Average

Exercise

Price Per

Share

 

 

 

 

 

 

 

 

Outstanding, December 31, 2024

 

 

37,174,468

 

 

$0.42

 

Warrants issued

 

 

2,571,023

 

 

 

0.13

 

Outstanding, March 31, 2025

 

 

39,745,491

 

 

$0.40

 

 

 

 

Warrants

(Underlying

Shares)

 

 

Weighted-

Average

Exercise

Price Per

Share

 

 

 

 

 

 

 

 

Outstanding, December 31, 2023

 

 

28,584,580

 

 

$0.50

 

Warrants issued

 

 

900,000

 

 

 

0.30

 

Warrants expired

 

 

(196,000)

 

 

0.25

 

Outstanding, March 31, 2024

 

 

29,288,580

 

 

$0.50

 

 

 
18

Table of Contents

 

Warrants Issued in 2025

 

During the three months ended March 31, 2025, the Company issued 2,571,023 warrants pursuant to the March Purchase Agreement.

 

Warrants Issued in 2024

 

During the three months ended March 31, 2024, the Company issued 900,000 warrants to Richard Blumberg, a related party, pursuant to a consulting agreement. See Note 6, “Commitments and Contingencies” for additional information.

 

4. STOCK OPTIONS

 

The Company’s Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The aggregate number of common shares that may be issued or reserved pursuant to stock option or other awards under the plan may not exceed 2,500,000 common shares. As of March 31, 2025, 500,000 of the outstanding stock options were granted outside of the Plan and the shares available for issuance under the Plan were 116,364.

 

The following tables summarize the Company’s stock option activity and related information for the three months ended March 31, 2025 and 2024:

 

 

 

Number of

Shares

 

 

Weighted-

Average

Exercise Price

Per Share

 

 

Weighted-

Average

Remaining

Contractual

Life

 

Aggregate

Intrinsic Value of

In-the-Money

Options 

(in thousands)

 

 

 

 

 

 

 

 

Options outstanding as of December 31, 2024

 

 

2,883,636

 

 

$0.35

 

 

6.3 years

 

$-

 

Options outstanding as of March 31, 2025

 

 

2,883,636

 

 

$0.35

 

 

6.0 years

 

$-

 

Options exercisable as of March 31, 2025

 

 

2,354,318

 

 

$0.39

 

 

5.4 years

 

$-

 

 

 

Number of

Shares

 

 

Weighted-

Average

Exercise Price

Per Share

 

 

Weighted-

Average

Remaining Contractual

Life

 

Aggregate

Intrinsic Value of

In-the-Money

Options

 (in thousands)

 

 

 

 

 

 

 

 

Options outstanding as of December 31, 2023

 

 

2,338,636

 

 

$0.41

 

 

6.5 years

 

$-

 

Options outstanding as of March 31, 2024

 

 

2,338,636

 

 

$0.41

 

 

6.3 years

 

$-

 

Options exercisable as of March 31, 2024

 

 

1,923,864

 

 

$0.44

 

 

5.7 years

 

$-

 

  

 
19

Table of Contents

 

The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price as of March 31, 2025 and the exercise price, multiplied by the number of options. As of March 31, 2025, there was $90,201 of unrecognized stock-based compensation expense. Such costs are expected to be recognized over a weighted average period of approximately 1.4 years.

 

The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. During the three months ended March 31, 2025 and 2024, the Company recognized expense for stock options of $19,296 and $14,837, respectively.

 

5. LITIGATION AND CLAIMS

 

From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular year.

 

As of March 31, 2025, and December 31, 2024, there was no accrual recorded for any potential losses related to pending litigation.

 

6. COMMITMENTS AND CONTINGENCIES

 

Operating Leases

 

Our corporate offices, which also comprise our administrative, research and development, marketing and production facilities, are located on a 12,835 square foot leased property. Total operating lease cost recognized for this was $27,351 for the three months ended March 31, 2025 and 2024. The table below presents total operating lease right-of-use assets and lease liabilities as of March 31, 2025 and December 31, 2024:

 

 

 

(in thousands)

 

 

 

March 31,

2025

 

 

December 31,

2024

 

Operating lease right-of-use assets

 

$118

 

 

$141

 

Operating lease liabilities

 

$130

 

 

$155

 

 

The table below presents the maturities of operating lease liabilities as of March 31, 2025:

 

 

 

(in

thousands)

 

 

 

Operating

 

 

 

Leases

 

 

 

$-

 

2025 (remaining)

 

 

89

 

2026

 

 

50

 

Total future lease payments

 

 

139

 

Less: discount

 

 

(9)

Total lease liabilities

 

$130

 

 

 
20

Table of Contents

 

The table below presents the weighted-average remaining lease term and discount rate used in the calculation of operating lease right-of-use assets and lease liabilities as of March 31, 2025 and December 31, 2024

 

 

 

March 31,

2025

 

 

December 31,

2024

 

Weighted average remaining lease term (years)

 

 

1.2

 

 

 

1.4

 

Weighted average discount rate

 

 

11.4%

 

 

11.4%

 

Related Party Contracts

 

During the year ended December 31, 2024, the Company issued promissory notes totaling $75,000 to members of the Board of Directors. In connection with the March Purchase Agreement, the Company entered into agreements to exchange the outstanding debt for common stock and warrants. See Note 9, “Related Party Debt” for additional details.

 

On June 5, 2016, the Company entered into a license agreement with Shenghuo Medical, LLC pursuant to which the Company granted Shenghuo an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Under the terms of the license agreement, once Shenghuo was capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, Shenghuo would pay the Company a royalty equal to $2.00 or 20% of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within Shenghuo’s exclusive territories. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s board of directors (current director Richard Blumberg is the designee).

 

On September 6, 2016, the Company entered into a royalty agreement with one of its directors, John Imhoff, and another stockholder, Dolores Maloof, pursuant to which the Company sold to them a royalty of future sales of single-use cervical guides for LuViva. Under the terms of the royalty agreement, and for consideration of $50,000, the Company will pay them an aggregate perpetual royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each cervical guide that the Company sells (or that is sold by a third party pursuant to a licensing arrangement with the Company).

 

On January 22, 2020, the Company entered into a promotional agreement with a related party, which is partially owned by Mr. Blumberg, to provide investor and public relations services for a period of two years. As compensation for these services, the Company agreed to issue a total of 5,000,000 warrants, broken into four tranches of 1,250,000. The warrants have a strike price of $0.25 and were subject to vesting based upon the close of the Series D offering and a minimum share price based on the 30-day VWAP. If the minimum share price per the terms of the agreement is not achieved, the warrants will expire three years after the scheduled issuance date. The warrants were valued using the Black Scholes model on the grant date of January 22, 2020. As of March 31, 2025, unrecognized consulting expense associated with the agreement was nil and 2,500,000 of the warrants had been issued, of which 1,750,000 were issued to Mr. Blumberg and 750,000 were issued to non-related parties.

 

On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg. As a result of the consulting agreement Mr. Blumberg provided a non-refundable payment of $350,000 to the Company in exchange for the following: (1) 3,600,000 3-year warrants with exercise prices ranging from $0.30 - $0.60, and (2) 1,600,000 common stock shares. On September 30, 2021, the Company and Mr. Blumberg entered into an amended agreement, pursuant to which issuance of the warrants and common shares became predicated on Mr. Blumberg’s assistance in helping the Company obtaining financing or a series of financings resulting in minimum receipts of at least $1.0 million. Upon receipt of the funds, the Company agreed to issue the common shares and warrants owed to Mr. Blumberg in four equal tranches, to be issued every six months, beginning six months after the financing transaction. On November 11, 2022, the Company and Mr. Blumberg entered into an amended agreement, upon which the exercise prices of the warrants were changed to $0.30. The Company estimated the fair value of the modified warrants using the Black-Scholes option pricing model and the following assumptions:

 

Expected term (years)

 

 

3.0

 

Volatility

 

 

108.7%

Risk-free interest rate

 

 

4.3%

Dividend yield

 

 

0.0%

 

 
21

Table of Contents

 

During the three months ended March 31, 2025 and 2024, the Company issued nil and 900,000 warrants to Mr. Blumberg pursuant to the agreement. Total unrecognized expense for the warrants was nil as of March 31, 2025.

 

On August 24, 2022, the Company entered into an agreement with Ironstone Capital Corp. and Alan Grujic (the “Advisory Group”) whereby the Advisory Group agreed to perform marketing and investor relations services over a term of twelve months, commencing on the closing of a financing of at least $2.5 million. In consideration for these services, the Company issued 800,000 warrants (“first tranche of warrants”) with an exercise price of $0.50 to Mr. Grujic, which were due within 10 business days of closing the financing transaction (the “Transaction”) that took place in September 2022. In the event the Company’s 20 trading day variable weighted average price (“VWAP”) exceeds $1.00 within one year of the closing of the financing, the Company would have issued 600,000 warrants (“second tranche of warrants”) with an exercise price of $0.75 to Mr. Grujic. In the event the Company’s 20 trading day VWAP exceeds $1.50 within two years of the closing of the financing, the Company will issue an additional 600,000 warrants (“third tranche of warrants”) to Mr. Grujic. Once issued, the warrants vest immediately and will expire two years from the date of issuance. If the Company’s U.S. clinical study is not completed and filed with the U.S. FDA or if the Chinese NMPA (formerly Chinese FDA) approval is not granted by each due date for reaching each respective pricing milestone, then the due date for reaching each milestone shall be extended by six months. As of March 31, 2025, the deadline to achieve the stock price of $1.50 has passed and the second tranche warrants will therefore not be issued.

 

Pursuant to the agreement, the Company also agreed to pay the Advisory Group $2,000 per month for 12 months, starting the month after the closing of the Transaction. Subsequently, the agreement was amended to extend the term of the agreement to September of 2024. On November 1, 2024, the Company entered into a new consulting agreement with Ironstone Capital Corp., pursuant to which the Company agreed to pay $2,500 per month for continued advisory and consulting services, for a term of six months.

 

The Company estimated the fair value of the first tranche warrants issued in September 2022 using the Black-Scholes option pricing model with the following assumptions:

 

Expected term (years)

 

 

2.0

 

Volatility

 

 

173.0%

Risk-free interest rate

 

 

3.4%

Dividend yield

 

 

0.0%

 

Expense related to the first tranche of warrants was recognized in prior years. Unrecognized expense related to the first tranche warrants was nil as of March 31, 2025.

 

The Company estimated the fair value of the second tranche warrants using the Binomial Lattice model with the following assumptions:   

 

Expected term (years)

 

 

1.0

 

Volatility

 

 

144.4%

Risk-free interest rate

 

 

3.6%

Dividend yield

 

 

0.0%

 

Expense related to the second tranche of warrants was recognized in prior years. Unrecognized expense related to the first tranche warrants was nil as of March 31, 2025.

 

The Company estimated the fair value of the third tranche warrants using the Binomial Lattice model with the following assumptions:  

 

Expected term (years)

 

 

2.0

 

Volatility

 

 

172.1%

Risk-free interest rate

 

 

3.6%

Dividend yield

 

 

0.0%

 

 
22

Table of Contents

 

The Company recognized expense for the third tranche of warrants of nil and $15,466 during the three months ended March 31, 2025 and 2024, respectively. Unrecognized expense for the third tranche of warrants was nil as of March 31, 2025.

 

Other Commitments

 

On July 24, 2019, the Company agreed to grant Shandong Yaohua Medical Instrument Corporation (“SMI”) (1) exclusive manufacturing rights, excepting the disposable cervical guides for the Republic of Turkey, and the final assembly rights for Hungary, and (2) exclusive distribution and sales for LuViva in jurisdictions, subject to the terms and conditions described below.

 

First, SMI shall complete the payment for parts, per the purchase order, for five additional LuViva devices. Second, in consideration for the $885,144 that the Company received, SMI will receive 12,147 shares of common stock. Third, SMI shall honor all existing purchase orders it has executed to date with the Company, in order to maintain jurisdiction sales and distribution rights. If SMI needs to purchase cervical guides, then it will do so at a cost including labor, plus ten percent markup. The Company will provide 200 cervical guides at no cost for the clinical trials. Fourth, the Company and SMI will make best efforts to sell devices after NMPA approval. With an initial estimate of year one sales of 200 LuViva devices; year two sales of 500 LuViva devices; year three sales of 1,000 LuViva devices; and year four sales of 1,250 LuViva devices. Fifth, SMI shall pay for entire costs of securing approval of LuViva with the Chinese FDA. Sixth, SMI shall arrange, at its sole cost, for a manufacturer in China to build tooling to support manufacturing. In addition, SMI retains the right to manufacture for China, Hong Kong, Macau and Taiwan, where SMI has distribution and sales rights. For each single-use cervical guide sold by SMI in the jurisdictions, SMI shall transfer funds to escrow agent at a rate of $1.90 per device chip. If within 18 months of the license’s effective date, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Commercialization is defined as: filing an application with the Chinese FDA for the approval of LuViva; any assembly or manufacture of the devices or disposables that begins in China; and purchase of at least 10 devices and disposables for clinical evaluations and regulatory use and or sales in the jurisdictions.

 

On August 12, 2021, the Company executed an amendment to its agreement with SMI. Under the terms of the amended agreement, the parties agreed that if by October 30, 2022, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. On March 3, 2023, the Company entered into a third amendment with SMI pursuant to which the Company extended the deadline for SMI to achieve commercialization of LuViva in China to April 30, 2024.

 

On February 17, 2024, the Company entered into a fourth amendment to the agreement with SMI. Under the terms of the amended agreement, SMI agreed to pay the Company $531,100 on or prior to March 15, 2024. On March 18, 2024, SMI, through SMI’s authorized distribution partner, initiated a wire payment of $330,000 in partial satisfaction of $531,100 owed to the Company. The payment was received by the Company on March 20, 2024. As the full payment was not received by March 15, 2024, the Company had the right to terminate the agreement with two weeks’ notice to SMI, however the Company did not exercise this option. 

 

The amended agreement also provides for a timeline for the Company to deliver inventory during 2024, including LuViva devices and components, as well as approximately 1,640,000 RFID chips. In consideration, SMI agreed to pay a total of $4.4 million during 2024, including the payment due on March 15, 2024.

 

 
23

Table of Contents

 

On March 27, 2024, the parties entered into a Standstill Agreement (the “Standstill Agreement”). The parties agreed that SMI will make a nonrefundable payment of $100,000 to the Company prior to March 31, 2024. In exchange, the Company will not initiate any legal proceedings, including but not limited to filing a lawsuit, obtaining a judgement, or enforcing any security interest, as related to the March shortfall in payments of $201,100, until April 30, 2024. Upon paying $100,000, SMI will have the option to extend the Standstill Agreement until June 15, 2024 by making a nonrefundable payment to the Company of $150,000. One additional payment of $150,000 may be made to extend the standstill rights until July 30, 2024, if mutually agreed upon. If SMI is unable to make the payments pursuant to the Standstill Agreement, the Company agreed to seek loans on behalf of SMI to cover the payments. SMI agreed to reimburse the Company for these loans along with all expenses associated with them within three months of the loans being issued as long as the loans are used solely for (1) parts for LuViva devices to be used by SMI for marketing and promotional activities, or (2) labor or consulting fees connected to providing parts, assemblies of devices or disposables to SMI. Additionally, SMI confirmed its commitment to make payments to GTI of at least $4.0 million during 2024 and as part of this commitment will make payments of $200,000 and $500,000 by the end of May 2024 and July 2024, respectively, to ensure that the program commercialization proceeds according to schedule.  

 

On April 26, 2024, the parties extended the Standstill Agreement (“Standstill Extension”) until July 30, 2024, contingent on payments from SMI totaling $770,000 on or before July 30, 2024. In addition, because SMI did not make its scheduled payment of $100,000 on or before March 31, 2024, the Company can place a 25% surcharge on the cost of goods and services already paid for by SMI. Additionally, the Standstill Extension reduced the number of RFID chips the Company committed to shipping by 240,000 and reduced the total amount due from SMI in 2024 by $247,545. The other terms from the Amendment and Standstill Agreement remained intact.

 

On October 21, 2024, the Company executed an agreement with SMI (the “Agreement”), which supersedes all previous agreements, other than existing purchase orders (except those as modified and summarized below). Pursuant to the Agreement, the Company plans to execute a purchase agreement with a distributor of SMI for 35 base units, connected, aligned, calibrated and tested (“Completed Instrumentation Packages”). SMI, to obtain the license for global manufacturing rights and exclusive distribution of LuViva within certain jurisdictions, agreed to: 

 

 

1.

Meet an established schedule for minimum sales of the product in China.

 

2.

Establish a manufacturing capability for the manufacture of LuViva and its accessories including the single use disposable Cervical Guide “Disposables” or “Accessories”).

 

3.

Apply for NMPA approval for LuViva no later than October 30, 2024. Said application was filed by SMI with NMPA on October 16, 2024.

 

Under the terms of the agreement, the Handheld Unit and Base Unit constitute an Instrumentation Package or “IP”. An IP and mobile cart with a monitor constitute a fully functional LuViva device ready for sale. SMI will be responsible for the manufacture of the mobile carts that house the IPs and the display monitor. All active purchase orders will be revised to include 100 IPs to be provided by the Company to SMI and/or its distribution partners to meet expected demand for the end of 2024 and 2025, as summarized below: 

 

 

1.

Forty-seven (47) of the 100 IPs will be provided by the Company to SMI, at an approximate price of $1,351,250; The number of IPs may be reduced if the full payment is delayed beyond the end of 2024.

 

2.

Thirty-five (35) of the 100 IPs will be provided by the Company to SMI or to one of SMI’s distributors, at a total price of $700,000.

 

3.

Eighteen (18) of the 100 IPs will be provided to SMI at no additional charge, beyond what has already been paid by SMI.

 

To meet demand for the remainder of 2024 and for the first half of 2025, SMI agreed to purchase a minimum of 500,000 RFID chips, at prices ranging between $1.00 and $1.40 per chip. To meet demand for the second half of 2025, SMI agreed to purchase an additional 100 IPs and 1,000,000 RFID chips, at prices ranging between $1.00 and $1.40 per chip. SMI agreed to pay a minimum of $400,000 to the Company prior to December 31, 2024, to cover additional components, devices and costs incurred by the Company. On January 3, 2025, after confirming with SMI that no payment was forthcoming, the Company notified SMI in writing that the failure to make this payment constituted a breach of the October 21, 2024 Agreement. SMI remained in breach of the agreement as of March 31, 2025.

 

 
24

Table of Contents

 

Beginning in 2026 and extending into 2030, to preserve its licensing rights, SMI shall be committed to the minimum LuViva Cervical Guide Radio Frequency Identification Chips and Royalty Sales (“RFID Chips”) of the single-use Cervical Guide Chip, at a sale price to SMI at $1.00, as specified in the table below: 

 

Year

 

Cumulative Number of Devices

Placed or Sold

 

 

Cumulative Resulting

Minimum Tests

 

 

Cumulative Minimum Cervical

Guide Royalty Payments to GTI

 

2026

 

 

300

 

 

 

1,440,000

 

 

$1,440,000

 

2027

 

 

400

 

 

 

5,040,000

 

 

$4,480,000

 

2028

 

1500

 

 

 

15,840,000

 

 

$15,840,000

 

2029

 

3000

 

 

 

37,440,000

 

 

$37,440,000

 

2030

 

4000

 

 

 

66,240,000

 

 

$66,240,000

 

 

During the three months ended March 31, 2025, the Company and SMI agreed to apply previous payments of $180,000 towards reimbursement of expenses the Company incurred in prior periods. As a result of this agreement, the Company recognized $180,000 of deferred revenue in income, which is included in “Other income” during the three months ended March 31, 2025. 

 

On May 8, 2025, the Company and SMI signed an extension agreement that becomes effective once SMI or its partners/investors make certain cash payments in accordance with purchase orders issued by SMI and its partners.  Once the required payments are made, the agreement allows for an extension until September 30, 2025. See Note 13, “Subsequent Events” for details.

 

Contingencies

 

The conflict in Ukraine, which has already had an impact on financial markets, could result in additional repercussions in our operating business, including delays in obtaining regulatory approval to market our products in Russia. The future impact of the conflict is highly uncertain and cannot be predicted, and we cannot provide any assurance that the conflict will not have a material adverse impact on our operations or future results or filings with regulatory health authorities.  

 

Tariffs imposed and/or publicly contemplated by the U.S. government in the first quarter of 2025, particularly those affecting imports from China, create significant uncertainty with respect to future tax and trade regulations and the potential competitive effects of such actions. Although the countries in which our products are manufactured or imported may from time to time impose additional quotas, duties, tariffs, or other restrictions, or adversely modify existing ones, we have established an auxiliary manufacturing site in Hungary. This strategic initiative helps mitigate our exposure to currently imposed tariffs, particularly those targeting Chinese imports, and limits the overall impact on our operations. Nevertheless, it remains unclear what the U.S. administration or foreign governments specifically will or will not do with respect to tariffs, tax policies, or other international trade agreements, regulations, and policies. A trade war, other governmental actions related to tariffs or international trade agreements, or changes in U.S. or foreign social, political, regulatory and economic conditions—especially as they relate to manufacturing and investment—could still materially adversely affect the Company’s business, financial condition, operating results, and cash flows.

 

7. NOTES PAYABLE

 

Short-term Promissory Notes

 

On July 23, 2024, the Company issued a promissory note totaling $50,000 to an unaffiliated third party. The promissory note accrued total interest of $5,000 and matured on February 1, 2025. Monthly payments of $10,000 were due on the note, beginning September 1, 2024 until January 1, 2025, while the interest payment was due on February 1, 2025. The holder of the promissory note also received 60,000 common stock purchase warrants, which have an exercise price of $0.25 and will expire on August 1, 2028. The warrants, which had an estimated fair value of $6,329, were recorded as a discount on the note payable.  The Company estimated the fair value of the warrants using the Black-Scholes option pricing model with the following assumptions:

 

Expected term (years)

 

 

4.0

 

Volatility

 

 

397.3%

Risk-free interest rate

 

 

3.9%

Dividend yield

 

 

0.0%

 

 
25

Table of Contents

 

On July 4, 2024, the Company entered into a premium finance agreement to finance its insurance policies totaling $129,556. Monthly payments of $12,025 are due on the note, including interest incurred at a rate of 8.8%. The note, which matures on May 4, 2025, had an outstanding balance of $23,962 and $59,255 as of March 31, 2025 and December 31, 2024, respectively.

 

Long-term Promissory Notes

 

On April 15, 2024, the Company entered into an exchange agreement with a former employee, whereby the former employee agreed to exchange outstanding amounts due to him for deferred compensation in the amount of $81,768 for an $87,162 promissory note dated April 15, 2024. Beginning on May 5, 2024, monthly payments of $2,000 are due on the note until its maturity date. The promissory note, which accrues interest at a rate of 6.0% per annum, matures on May 5, 2028. The total balance of the promissory note was $65,182 as of March 31, 2025, of which $24,000 is included in “Short-term notes payable” on the condensed consolidated balance sheets and $41,162 is included in “Long-term notes payable.” The total principal balance of the promissory note was $71,162 as of December 31, 2024, of which $24,000 is included in “Short-term notes payable” on the condensed consolidated balance sheets and $47,162 is included in “Long-term notes payable.” Total accrued interest on the promissory note was $4,462 and $3,424 as of March 31, 2025 and December 31, 2024, respectively.

 

The following tables summarize notes payable (in thousands):

 

 

 

Notes Payable

(in thousands)

 

 

 

March 31,

2025

 

 

December 31,

2024

 

Short-term promissory notes

 

$-

 

 

$10

 

Deferred compensation note

 

 

65

 

 

 

71

 

Insurance policy financing

 

 

24

 

 

 

59

 

Debt discount

 

 

-

 

 

 

(1)

Total

 

 

89

 

 

 

139

 

 

 

 

 

 

 

 

 

 

Less: Current portion of notes payable

 

 

(48)

 

 

(92)

Total long-term notes payable

 

$41

 

 

$47

 

 

Future debt obligations at March 31, 2025 for notes payable are as follows:

 

Year

 

Amount

(thousands)

 

2025 (remaining)

 

 

42

 

2026

 

 

24

 

2027

 

 

23

 

Total

 

$89

 

 

 
26

Table of Contents

  

8. CONVERTIBLE DEBT

 

10% Senior Unsecured Convertible Debenture

 

On May 17, 2021, the Company issued 10% Senior Unsecured convertible debentures to investors, which matured on May 17, 2024 (the “Maturity Date”). The Company subscribed $1,130,000 of the $1,000 convertible debentures. The terms of the debentures are as follows: 1) the principal amount of some or all of the convertible debentures and accrued interest are convertible into shares of common stock at the holder’s option, at a price of $0.50 per common stock share (the “conversion price”), subject to adjustment in certain events, at any time prior to maturity date; 2) upon successful uplist to a U.S. National Exchange, the note will automatically convert into the uplisting financing; 3) each debenture unit included 1,000 common stock warrants with an exercise price of $0.80 and an expiration date of May 17, 2023; 4) if a Change of Control (as defined in the Convertible Debenture Certificate) occurs prior to the Maturity Date, unless the holder elects in writing to convert the Convertible Debentures into shares of common stock, the Company will repay in cash upon the closing of such Change of Control all outstanding principal and accrued interest under each Convertible Debenture plus a Change of Control premium equal to an additional 3% of the outstanding principal sum under such Convertible Debenture. Prior to the closing of an Change of Control, in lieu of repayment as set forth in the preceding sentence, the holder has the right to elect in writing to convert, effective immediately prior to the effective date of such Change of Control, all outstanding principal and accrued Interest under the Convertible Debentures into shares of common stock at the Conversion Price; 5) Subject to a holder’s option of electing conversion prior to the Redemption Date (as such term is defined below), on or after the date that is 24 months from the Closing Date if the daily volume weighted average trading price of the shares of common stock is $1.50 per share of common stock or more for each trading day over a 30 consecutive trading day period, the Company may, at any time (the “Redemption Date”), at its option, redeem all, or any portion of the Convertible Debentures for either: (i) a cash payment (in the form of a certified cheque or bank draft) that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date; or (ii) by issuing and delivering shares of common stock to the holders of Convertible Debentures at a deemed price of $0.50 per share of common stock that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date, or any combination of (i) or (ii), upon not less than 30 days and not more than 60 days prior written notice in the manner provided in the Debenture Certificate, to the holder of Convertible Debentures.

 

At March 31, 2025 and December 31, 2024, the balance due on the 10% Senior Secured Convertible Debenture was $1,130,000 and total accrued interest was $154,810 and $103,960, respectively. After the May 17, 2024 maturity date, the interest rate increased to the default rate of 18.0%. The bond payable discount and unamortized debt issuance costs as of March 31, 2025 and December 31, 2024 are presented below (in thousands):

 

 

 

Senior Secured Convertible

Debenture

 

 

 

March 31,

2025

 

 

December 31,

2024

 

10% Senior Unsecured Convertible Debentures

 

$1,130

 

 

$1,130

 

Unamortized debt issuance costs

 

 

-

 

 

 

-

 

Debt discount

 

 

-

 

 

 

-

 

Senior Unsecured Convertible Debenture

 

$1,130

 

 

$1,130

 

  

As of March 31, 2025 and December 31, 2024, the balance of the Senior Unsecured Convertible Debenture is included in “Short-term convertible notes payable in default” within the condensed consolidated balance sheets.

 

 
27

Table of Contents

 

Convertible Promissory Notes

 

The following table summarizes convertible promissory notes outstanding as of March 31, 2025 and December 31, 2024:

 

 

 

March 31,

2025

 

 

December 31,

2024

 

Convertible promissory notes

 

$246

 

 

$330

 

Unamortized debt issuance costs

 

 

(1)

 

 

(3)

Debt discount

 

 

(137)

 

 

(196)

Convertible promissory notes

 

$108

 

 

$131

 

 

1800 Diagonal Lending LLC Notes

 

On July 22, 2024, the Company entered into a securities purchase agreement and contingently convertible note with 1800 Diagonal Lending LLC (“Diagonal Lending”). The convertible note issued to Diagonal Lending had a total principal balance of $62,100 and an original issue discount of $8,100. The note, which will accrue total interest of $8,694, will mature on May 30, 2025. A payment of $35,397 was due on the note on January 30, 2025. The remaining balance due, including accrued interest, will be paid in monthly payments of $8,849 from February 28, 2025 through May 30, 2025. The note may be prepaid at any time with no prepayment penalty. Any amount of principal or interest on the note which is not paid when due will bear interest at the rate of the lessor of 22.0% or the maximum permitted by law. The Company may not sell, lease, or otherwise dispose of any significant portion of its assets outside of the ordinary course of business without the express permission of Diagonal Lending. In the event of default, the note will become immediately due and payable in an amount equal to 150.0% times the sum of the then outstanding principal, accrued interest and default interest. 

 

On June 11, 2024, the Company entered into a securities purchase agreement and contingently convertible note with Diagonal Lending (together with the July 22, 2024 note, the “Notes”). The convertible note issued to Diagonal Lending had a total principal balance of $100,050 and an original issue discount of $13,050. The note, which will accrue total interest of $14,007, will mature on April 15, 2025. A payment of $57,029 was due on the note on December 15, 2024. The remaining balance due, including accrued interest, will be paid in monthly payments of $14,257 from January 15, 2025 through April 15, 2025. The note may be prepaid within 120 days of issuance for a discount of 2.0-3.0 % of the principal and accrued interest due. Any amount of principal or interest on the note which is not paid when due will bear interest at the rate of the lessor of 22% or the maximum permitted by law. The Company may not sell, lease, or otherwise dispose of any significant portion of its assets outside of the ordinary course of business without the express permission of Diagonal Lending. In the event of default, the note will become immediately due and payable in an amount equal to 150.0% times the sum of the then outstanding principal, accrued interest and default interest. 

 

In the event of default, the unpaid portion of the Notes and accrued interest is convertible into shares of common stock at a conversion rate equal to the variable conversion price. The variable conversion price is equal to the lowest closing price of our common stock during the ten days prior to the conversion date multiplied by 65.0%. The Company assessed the embedded conversion features and determined that they are not considered clearly and closely related to the host notes and therefore meet the definition of derivatives. Therefore, these embedded conversion features are required to be bifurcated from the note and accounted for separately as a derivative liability. The Company estimated the fair value of the derivative liabilities on the issuance dates of the Notes and recorded them as discounts that net against the convertible notes. The Company is required to remeasure the derivative liabilities to their then fair values at each subsequent balance sheet date, through an adjustment to current earnings (see Note 11 for further details on the Company’s fair value measurement).

 

At March 31, 2025, the balance due on the Notes was $30,517 and is presented net of total unamortized debt discounts and debt issuance costs of $4,586 within “Short-term convertible debt, net of discounts” on the condensed consolidated balance sheet. At December 31, 2024, the balance due on the Notes was $115,681 and is presented net of total unamortized debt discounts and debt issuance costs of $16,423 within “Short-term convertible debt, net of discounts” on the condensed consolidated balance sheet. Total accrued interest as of March 31, 2025 and December 31, 2024 was $857 and $7,518, respectively.  

 

 
28

Table of Contents

 

Flynn D. Case Living Trust Convertible Note

 

On October 10, 2024, the Company issued a promissory note totaling $200,000 to Flynn D. Case Living Trust, an unaffiliated third party (the “Holder”). The promissory note had a maturity date of October 10, 2025 and accrued interest at a rate of 12.0% per annum. Monthly payments of $20,000 were due on the note, beginning November 30, 2024 until August 31, 2025, while the interest payment was due on or before October 10, 2025. If not repaid by the maturity date, the unpaid balance of the note accrued interest at a rate of 16.0% per annum. With the Holder’s permission, the promissory note may be prepaid in full or in part without penalty or premium. The Holder also received 667,667 common stock purchase warrants, which have an exercise price of $0.25 and will expire on October 9, 2028. The warrants, which had an estimated fair value of $109,356, were recorded based on relative fair value as a discount on the note payable. The Company estimated the fair value of the warrants using the Black-Scholes option pricing model with the following assumptions:

 

Expected term (years)

 

 

4.0

 

Volatility

 

 

398.8%

Risk-free interest rate

 

 

3.9%

Dividend yield

 

 

0.0%

 

On December 5, 2024, the Company amended the payment terms of the convertible promissory note. In accordance with the amended agreement, payments of $75,000 plus accrued interest will be due on June 4, 2025 and December 4, 2025. The note will mature on June 4, 2026, upon which a final payment of $50,000 plus all accrued interest will be due. The Holder will have an option to convert the principal and accrued interest due on each payment date to common stock at the following conversion prices:

 

 

·

$75,000 plus interest accrued through June 4, 2025 may be converted at a price equal to the lower of $0.25 or a 25.0% discount on the average 10-day VWAP of the common stock immediately prior to the conversion date;

 

 

 

 

·

$75,000 plus interest accrued through December 4, 2025 may be converted at a price equal to the lower of $0.50 or a 20.0% discount on the average of the 10-day VWAP of the common stock immediately prior to the conversion date; and

 

 

 

 

·

$50,000 plus interest accrued through June 4, 2026 may be converted at a price equal to the lower of $0.75 or a 15.0% discount on the average of the 10-day VWAP of the common stock immediately prior to the conversion date.

 

The Company assessed the embedded conversion features and determined that they are not considered clearly and closely related to the host note and therefore meet the definition of derivatives. Therefore, these embedded conversion features are required to be bifurcated from the note and accounted for separately as a derivative liability. The Company estimated the fair value of the derivative liabilities on the date the amendment was executed and recorded them as discounts that net against the convertible note. The Company is required to remeasure the derivative liabilities to their then fair values at each subsequent balance sheet date, through an adjustment to current earnings (see Note 11 for further details on the Company’s fair value measurement).

 

At March 31, 2025, the balance due on the convertible promissory note was $200,000 and is presented net of total unamortized debt discounts of $133,366, of which $31,630 is included in “Short-term convertible debt, net of discounts” and $35,004 is included in “Long-term convertible debt, net of discounts” on the condensed consolidated balance sheets. At December 31, 2024, the balance due on the convertible promissory note was $200,000 and is presented net of total unamortized debt discounts of $183,176, of which $2,583 is included in “Short-term convertible debt, net of discounts” and $14,241 is included in “Long-term convertible debt, net of discounts” on the condensed consolidated balance sheets. Total accrued interest as of March 31, 2025 and December 31, 2024 was $7,733 and $1,733, respectively.

 

 
29

Table of Contents

 

Auctus Convertible Note

 

On December 17, 2019, the Company entered into a securities purchase agreement and convertible note with Auctus Fund, LLC (“Auctus’). The convertible note issued to Auctus was for a total of $2.4 million. The note may not have been prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which was not paid when due shall bore interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices equaled the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event could the variable conversion price be less than $0.15. If an event of default under this note occurred and/or the note was not extinguished in its entirety prior to December 17, 2020, the $0.15 price floor no longer applied.

 

On September 1, 2022, the Company agreed to exchange certain debt and equity owned by Auctus pursuant to an Exchange Agreement between the Company and Auctus (the “Exchange Agreement”). Immediately prior to the Exchange Agreement, Auctus held $1,228,183 of debt, including an early prepayment penalty of $350,000, default premiums of $281,256, and $91,555 in interest payable. Auctus agreed to reduce the amount owed to $710,911 and to revert the May 27, 2020 note to its original term. Additionally, Auctus agreed to exchange 8,775,000 warrants that were priced between $0.15 and $0.20 and the $350,000 prepayment penalty for 3,900,000 shares of common stock, warrants to purchase 3,900,000 shares of common stock at $0.50 per share and warrants to purchase 3,900,000 shares of common stock at $0.65 per share (the “Exchange”). As a result of the Exchange Agreement, Auctus forgave a default penalty of $225,444. Following the Exchange and Repayment, the Company will make payments to Auctus in four installments, over an 18-month period. During 2024, Auctus agreed to apply the payments to the principal portion of the debt before applying the funds to the accrued interest. As a result, management has reclassified a portion of the current and prior period outstanding debt to the accrued interest. 

 

The total outstanding balance of the convertible note was $15,000 as of March 31, 2025 and December 31, 2024. The balances are included within “Short-term convertible debt” on the condensed consolidated balance sheets. Total accrued interest on the Auctus convertible note was $116,787 and $116,412 as of March 31, 2025 and December 31, 2024, respectively.

 

9. RELATED PARTY DEBT

 

Short-Term Notes Payable Due to Related Parties

 

During the year ended December 31, 2024, the Company issued promissory notes totaling $75,000 to members of the Board of Directors. The promissory notes accrued interest at a rate of 9.0%. The holders of the promissory notes also received 75,000 common stock purchase warrants, which have exercise prices of $0.25 and will expire four years after issuance. The warrants, which had an estimated fair value of $8,800, were recorded as a discount on the note payables.  The Company estimated the fair value of the warrants using the Black-Scholes option pricing model with the following weighted-average assumptions:

 

Expected term (years)

 

 

4.0

 

Volatility

 

 

397.1%

Risk-free interest rate

 

 

3.9%

Dividend yield

 

 

0.0%

 

During the three months ended March 31, 2025, the Company entered into an exchange agreements with two members of the Board of Directors to exchange $50,000 of notes payable and accrued interest of $2,602 for 526,014 shares of common stock and 526,014 warrants to purchase up to 526,014 shares of common stock. The warrants, which were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share. During the three months ended March 31, 2025, the Company recorded a loss on extinguishment of debt of $31,928 for the exchange agreements, equal to the excess of fair value of the common stock and warrants over the value of the debt and accrued interest. The fair value of the warrants was estimated using the Black-Scholes valuation model, with the following assumptions:

 

Expected term (years)

 

 

4.0

 

Volatility

 

 

191.5%

Risk-free interest rate

 

 

4.0%

Dividend yield

 

 

0.0%

 

 
30

Table of Contents

 

The outstanding principal and associated debt discounts as of March 31, 2025 and December 31, 2024 are presented below (in thousands):

 

 

 

Short-Term Notes Payable

Due to Related Parties

 

 

 

March 31,

2025

 

 

December 31,

2024

 

Short-term promissory notes

 

$25

 

 

$75

 

Debt discount

 

 

(1)

 

 

(5)

Short-term notes payable due to related parties

 

$24

 

 

$70

 

  

Current Portion of Long-Term Debt, Related Parties

 

On July 14, 2018, the Company entered into an exchange agreement with Dr. Faupel, whereby Dr. Faupel agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $660,895 for a $207,111 promissory note dated September 4, 2018. On July 20, 2018, the Company entered into an exchange agreement with Dr. Cartwright, whereby Dr. Cartwright agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,499 for a $319,000 promissory note dated September 4, 2018 that incurs interest at a rate of 6.0% per annum.

 

On July 24, 2019, Dr. Faupel and Mr. Cartwright agreed to an addendum to the debt restructuring exchange agreement. Pursuant to this modification Dr. Faupel and Mr. Cartwright agreed to extend the note to be due in full on the third anniversary of that agreement.

 

On February 19, 2021, the Company entered into new promissory notes replacing the original notes from September 4, 2018, with Mark Faupel and Gene Cartwright. For Dr. Cartwright the principal amount on the new note was $267,085, the maturity date was February 18, 2023, and the interest rate was 6.0%. For Dr. Faupel the principal amount on the new note was $153,178, the maturity date was February 18, 2023, and the interest rate was 6.0%. Additionally, the Company exchanged $100,000 and $85,000 of the balances owed to Dr. Cartwright and Dr. Faupel for 100 and 85 shares of Series F-2 Preferred Stock, respectively.

 

On February 18, 2023, the Company amended the terms of the promissory notes held by Mark Faupel and Gene Cartwright. Under the terms of the new agreements, the promissory notes matured on February 18, 2025. On March 7, 2025, the Company amended the terms of the promissory note held by Mark Faupel. Under the terms of the new agreement, the promissory note will mature on February 18, 2026. The balance owed to Mr. Cartwright was overdue as of March 31, 2025.

 

 
31

Table of Contents

 

The tables below summarize the outstanding balance of debt owed to Dr. Faupel and Dr. Cartwright (in thousands):

 

For Dr. Faupel:

 

 

 

 

 

 

 

Salary

 

$134

 

Bonus

 

 

20

 

Vacation

 

 

95

 

Interest on compensation

 

 

67

 

Loans to Company

 

 

196

 

Interest on loans

 

 

149

 

Total outstanding prior to exchange

 

 

661

 

 

 

 

 

 

Amount forgiven in prior years

 

 

(454)

Amount exchanged for Series F-2 Preferred Stock

 

 

(85)

Total interest accrued through December 31, 2024

 

 

67

 

Balance outstanding at December 31, 2024

 

$189

 

 

 

 

 

 

Interest accrued through March 31, 2025

 

 

2

 

Balance outstanding at March 31, 2025

 

$191

 

 

For Dr.Cartwright

 

 

 

 

 

 

 

Salary

 

$337

 

Bonus

 

 

675

 

Loans to Company

 

 

528

 

Interest on loans

 

 

81

 

Total outstanding prior to exchange

 

 

1,621

 

 

 

 

 

 

Amount forgiven in prior years

 

 

(1,302)

Amount exchanged for Series F-2 Preferred Stock

 

 

(100)

Total interest accrued through December 31, 2024

 

 

108

 

Payments on outstanding debt

 

 

(25)

Balance outstanding at December 31, 2024

 

$302

 

 

 

 

 

 

Interest accrued through March 31, 2025

 

 

3

 

Balance outstanding at March 31, 2025

 

$305

 

 

On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Stock (convertible into 200,000 shares of common stock), and a $150,000 unsecured note. The note accrues interest at the rate of 6.0% (18.0% in the event of default) beginning on March 22, 2022 and is payable in monthly installments of $3,600 for four years, with the first payment due on March 15, 2022. The effective interest rate of the note is 6.18%.

 

During the three months ended March 31, 2025 and 2024, Mr. Fowler forgave $15,637 and $16,659 of the outstanding balance of deferred compensation, respectively. As of March 31, 2025, Mr. Fowler may forgive up to $48,604 of the remaining deferred compensation if the Company complies with the repayment plan described above. The reductions in the outstanding balance met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. As of March 31, 2025, the outstanding principal amount owed on the note was $33,753, which is included in “Current portion of long-term debt, related parties” in the condensed consolidated balance sheet. As of December 31, 2024, the outstanding principal amount owed on the note was $43,895, of which $41,489 is included in “Current portion of long-term debt, related parties” and $2,406 is included in “Long-term debt, related parties” in the condensed consolidated balance sheet.

 

 
32

Table of Contents

 

Future debt obligations at March 31, 2025 for debt owed to related parties are as follows:

 

Year

 

Amount 

(in

thousands)

 

 

 

 

 

2025 (remaining)

 

 

337

 

2026

 

 

193

 

Total

 

$530

 

 

10. INCOME (LOSS) PER SHARE OF COMMON STOCK

 

Basic net income (loss) per share attributable to common stockholders, amounts are computed by dividing the net income (loss) plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the year.

 

Diluted net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends, deemed dividends on preferred stock, after-tax interest on convertible debt and convertible dividends by the weighted average number of shares outstanding during the year, plus Series C-1, Series D, Series E, Series F and Series F-2 convertible preferred stock, convertible debt, convertible preferred dividends, warrants and stock options convertible into common stock shares.

 

During a period of net loss, basic and diluted earnings per share are the same as the assumed exercise of warrants and the conversion of convertible debt and preferred stock are anti-dilutive. For the three months ended March 31, 2025 and 2024, all stock options, convertible preferred stock, convertible debt and warrants were anti-dilutive and were therefore excluded from the computation of diluted loss per share. At March 31, 2025 and 2024, these instruments were convertible into 57,677,477 and 76,809,401 common shares, respectively.

 

The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except for per-share data):

 

 

 

Three Months Ended

March 31,

 

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

Net loss attributable to common shareholders

 

 

(463 )

 

 

(441 )

Basic weighted average number of shares outstanding

 

 

68,291

 

 

 

54,750

 

Net loss per share attributable to common shareholders (basic)

 

 

(0.01 )

 

 

(0.01 )

Diluted weighted average number of shares outstanding

 

 

68,291

 

 

 

54,750

 

Net loss per share attributed to common shareholders (diluted)

 

 

(0.01 )

 

 

(0.01 )

  

11. FAIR VALUE MEASUREMENTS

 

The convertible notes payable derivative liabilities are considered Level 3 measurements, due to the significant unobservable inputs in the valuation, which are based on a forecast of the Company’s future stock performance and, as the note payable is contingently convertible upon an event of default, management’s estimate of the likelihood and timing of conversion.

 

Based on the terms and provisions of the convertible notes payable, management built a pricing simulation that predicts the Company’s future stock prices using historical volatility. Our model is designed to utilize the Company’s best estimates of the timing and likelihood of a conversion of the notes payable to calculate the variable conversion price as of the future conversion date. 

 

 
33

Table of Contents

 

The key inputs to the valuation model that was utilized to estimate the fair value of the bifurcated conversion option included: 

 

 

·

The forecasted future stock prices were determined using historical stock prices and the Company’s equity volatility.

 

·

The expected conversion price was determined using the forecast and the contractual terms of the convertible note agreements.

 

·

The probability and timing of potential conversions are based on management’s best estimate of the future settlements of the convertible notes.

 

The following tables presents the fair value of the bifurcated conversion options as of March 31, 2025 and December 31, 2024:  

 

 

 

Fair Value at March 31, 2025

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative liability/bifurcated conversion options in connection with convertible promissory notes

 

$-

 

 

$-

 

 

$66

 

 

$66

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total short-term liabilities at fair value

 

$-

 

 

$-

 

 

$66

 

 

$66

 

 

 

 

 

Fair Value at December 31, 2024

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative liability/bifurcated conversion options in connection with convertible promissory notes

 

$-

 

 

$-

 

 

$118

 

 

$118

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total short-term liabilities at fair value

 

$-

 

 

$-

 

 

$118

 

 

$118

 

  

Derivative financial instruments and changes thereto recorded in the three months ended March 31, 2025 and 2024 include the following:

 

 

 

Three Months Ended 

March 31,

 

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

Fair value, beginning of period

 

$118

 

 

$-

 

Change in fair value of beneficial conversion features

 

 

(52)

 

 

-

 

 

 

 

 

 

 

 

 

 

Fair value, end of period

 

$66

 

 

$-

 

 

 
34

Table of Contents

 

12. SEGMENT REPORTING

 

The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision maker is the Chief Executive Officer and acting Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision maker does not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas. Since the Company operates as one operating segment, financial segment information, including profit or loss and asset information, can be found in the consolidated financial statements.

 

13. SUBSEQUENT EVENTS

 

Issuances of Promissory Notes

 

On April 1, 2025, the Company entered into a securities purchase agreement and contingently convertible note with 1800 Diagonal Lending LLC (“Diagonal Lending”). The convertible note issued to Diagonal Lending had a total principal balance of $149,500 and an original issue discount of $19,500. The note, which will accrue total interest of $16,445, will mature on January 30, 2026. A payment of $82,973 is due on the note on September 30, 2025. The remaining balance due, including accrued interest, will be paid in monthly payments of $20,743 from October 30, 2025 through January 30, 2026. Any amount of principal or interest on the note which is not paid when due will bear interest at the rate of the lessor of 22.0% or the maximum permitted by law. The Company may not sell, lease, or otherwise dispose of any significant portion of its assets outside of the ordinary course of business without the express permission of Diagonal Lending. In the event of default, the note and all accrued interest may be converted into shares of common stock, at a price equal to 65.0% multiplied by the lowest trading price of the common stock during the 10 trading days prior to the conversion date.

 

On May 1, 2025, the Company entered into a securities purchase agreement and contingently convertible note with 1800 Diagonal Lending LLC (“Diagonal Lending”). The convertible note issued to Diagonal Lending had a total principal balance of $120,750 and an original issue discount of $15,750. The note, which will accrue total interest of $13,282, will mature on February 28, 2026. A payment of $67,016 is due on the note on October 30, 2025. The remaining balance due, including accrued interest, will be paid in monthly payments of $16,754 from November 30, 2025 through February 28, 2026. Any amount of principal or interest on the note which is not paid when due will bear interest at the rate of the lessor of 22.0% or the maximum permitted by law. The Company may not sell, lease, or otherwise dispose of any significant portion of its assets outside of the ordinary course of business without the express permission of Diagonal Lending. In the event of default, the note and all accrued interest may be converted into shares of common stock, at a price equal to 65.0% multiplied by the lowest trading price of the common stock during the 10 trading days prior to the conversion date.

 

On May 2, 2025, the Company issued a promissory note totaling $75,000 to an unaffiliated third party (the “Holder”). The promissory note, which matures on May 2, 2026, will accrue interest at a rate of 12.0% per annum. In the event of a default, the interest rate will increase to 15.0%. At the discretion of the Company, on the maturity date the Company may give the Holder the option to convert the outstanding principal and accrued interest into shares of common stock at a conversion rate of $0.20 per share. The outstanding principal and accrued interest is due on the maturity date. The Holder also received 75,000 common stock purchase warrants, which have an exercise price of $0.20 and will expire on May 2, 2028.

 

Issuances of Common Stock

 

Subsequent to March 31, 2025, the Company issued 624,373 and 302,265 of common shares for payment of Series F and Series F-2 Convertible Preferred Stock, respectively.

 

Modification of Agreement with SMI

 

On May 8, 2025, Guided Therapeutics, Inc. (“GTI”) entered into an Extension Agreement with SMI, modifying the terms of their commercialization agreement dated October 21, 2024. The Extension Agreement was executed to address and cure SMI’s prior non-compliance with key obligations under the original agreement, including overdue payments and failure to demonstrate commercialization of GTI’s LuViva® Advanced Cervical Scan device in China.

 

Under the Extension Agreement, GTI and SMI agreed to new payment terms, including immediate payments of $100,000 for RFID chips and $30,000 for device parts by May 10, 2025, and a revised installment schedule for the remaining $300,000 balance. SMI also agreed to pay $1,351,250 for instrumentation packages by September 30, 2025. Additional milestones were established, including requirements to (i) demonstrate commercialization of LuViva in China by September 30, 2025, (ii) pass manufacturing inspections, and (iii) demonstrate the ability to manufacture cervical guides to GTI’s specifications by July 30, 2025.

 

The agreement provides for immediate termination and forfeiture of rights by SMI upon any breach, with no cure period, and requires the return of all LuViva-related materials upon such termination. All other terms of the October 21, 2024 agreement remain in effect unless expressly modified.

 

 
35

Table of Contents

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

FORWARD-LOOKING STATEMENTS

 

In addition to historical information, this Quarterly Report on Form 10-Q may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act), which provides a “safe harbor” for forward-looking statements made by us. All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, beliefs, business strategies, future events, business conditions, results of operations, financial position, business outlook, business trends, and other information, may be forward-looking statements. Words such as “might,” “will,” “may,” “should,” “estimates,” “expects,” “continues,” “contemplates,” “anticipates,” “projects,” “plans,” “potential,” “predicts,” “intends,” “believes,” “forecasts,” “future,” and variations of such words or similar expressions are intended to identify forward-looking statements. The forward-looking statements are not historical facts, and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Our expectations, beliefs, estimates, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, estimates, and projections will occur or can be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements.

 

These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or anticipated results, including those that may be set forth under "Risk Factors" below and elsewhere in this report, as well as in our annual report on Form 10-K for the year ended December 31, 2024 and this quarterly report on Form 10-Q. Examples of these uncertainties and risks include, but are not limited to:

 

 

·

access to sufficient debt or equity capital to meet our operating and financial needs;

 

·

the extent of dilution of the holdings of our existing stockholders upon the issuance, conversion or exercise of securities issued as part of our capital raising efforts;

 

·

the extent to which certain debt holders may call the notes to be paid;

 

·

the effectiveness and ultimate market acceptance of our products and our ability to generate sufficient sales revenues to sustain our growth and strategy plans;

 

·

whether our products in development will prove safe, feasible and effective;

 

·

whether and when we or any potential strategic partners will obtain required regulatory approvals in the markets in which we plan to operate;

 

·

our need to achieve manufacturing scale-up in a timely manner, and our need to provide for the efficient manufacturing of sufficient quantities of our products;

 

·

the lack of immediate alternate sources of supply for some critical components of our products;

 

·

our ability to establish and protect the proprietary information on which we base our products, including our patent and intellectual property position;

 

· 

The impact of the conflict between Russia and Ukraine on economic conditions in general and on our business operations;

 

·

the need to fully develop the marketing, distribution, customer service and technical support and other functions critical to the success of our product lines;

 

·

the dependence on potential strategic partners or outside investors for funding, development assistance, clinical trials, distribution and marketing of some of our products; and

 

·

other risks and uncertainties described from time to time in our reports filed with the SEC.

 

 
36

Table of Contents

 

These forward-looking statements reflect our management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this filing and are subject to risks and uncertainties. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

 

Forward-looking statements speak only as of the date the statements are made. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect thereto or with respect to other forward-looking statements.

 

The following discussion should be read in conjunction with our financial statements and notes thereto included elsewhere in this report.

 

OVERVIEW

 

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.

 

LuViva provides a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva improves patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care. We focus on two primary applications for LuViva: first, as a cancer screening tool in the developing world, where infrastructure to support traditional cancer-screening methods is limited or non-existent, and second, as a triage following traditional screening in the developed world, where a high number of false positive results cause a high rate of unnecessary and ultimately costly follow-up tests.

 

We are a Delaware corporation, originally incorporated in 1992 under the name “SpectRx, Inc.” and, on February 22, 2008, changed our name to Guided Therapeutics, Inc. At the same time, we renamed our wholly owned subsidiary, InterScan, which originally had been incorporated as “Guided Therapeutics.”

 

Since our inception, we have raised capital through the public and private sale of debt and equity, funding from collaborative arrangements, and grants.

 

Our prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. We have experienced operating losses since our inception in 1992 as SpectRx, Inc. and, as of March 31, 2025, we have an accumulated deficit of approximately $154.2 million. To date, we have engaged primarily in research and development efforts and the early stages of marketing our products. We do not have significant experience in manufacturing, marketing or selling our products. We may not be successful in growing sales for our products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. Our products may not ever gain market acceptance and we may not ever generate significant revenues or achieve profitability. The development and commercialization of our products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. We expect our operating losses to continue for the foreseeable future as we continue to expend substantial resources to complete commercialization of our products, obtain regulatory clearances or approvals, build our marketing, sales, manufacturing and finance capabilities, and conduct further research and development.

 

 
37

Table of Contents

 

Our product revenues to date have been limited. Our historical and expected future revenue has been and will be derived from sales of LuViva devices and disposables.

 

Current Demand for LuViva

 

Based on written agreements and ongoing discussions with SMI, we currently hold and expect to generate additional purchase orders which we expect to result in actual sales of approximately $2.0 million within the next twelve months. We cannot be assured that we will generate all or any of these additional purchase orders, or that existing orders will not be canceled by the distributors or that parts to build product will be available to meet demand, such that existing orders will result in actual sales. Because we have a short history of sales of our products, we cannot confidently predict future sales of our products beyond this time frame and cannot be assured of any particular number of sales. Accordingly, we have not identified any particular trends with regard to sales of our products. In order to increase demand for LuViva, we are focused on three primary markets: the United States, China and Europe. In addition, we have recently received sales orders from Turkey and Indonesia, for which we have received the necessary regulatory approvals and are preparing to fulfill. These orders are expected to result in approximately $500,000 in revenue for 2025. When combined with sales to our Chinese partner, these constitute what we view as the current demand for our products.

 

In the United States, the Company is actively pursuing FDA approval by conducting a clinical trial involving approximately 400 study participants, with the exact number depending in part on the numbers of women in the study both with and without cervical disease. The study protocol was drafted with input from FDA and physicians at the clinical centers that are participating in the study. In 2023, FDA completed its review of the protocol and had no further recommendations or questions. Also in 2023, four clinical sites agreed to participate in the study and all four of the study sites were fully IRB approved. The protocol was also approved by an independent, nationally recognized institutional review board. All four sites have received LuViva devices and have been trained in their use. All four sites have undergone multiple clinical study monitoring visits by the Company’s clinical study monitors. Clinical study monitoring visits are required by FDA to ensure that the study is being conducted under FDA guidelines and in compliance with the study protocol. Findings from the ongoing clinical study monitoring visits include:

 

 

1.

As of May 1, 2025, approximately 360 patients have been enrolled and tested, which represents approximately ninety percent of the 400 anticipated patients needed to complete the study.

 

 

 

 

2.

There have not been any adverse events reported related to the use of LuViva.

 

 

 

 

3.

All four monitored clinical study sites are adhering to the study protocol and are completing the necessary case report forms according to FDA standards.

 

 

 

 

4.

All four study sites have met minimum enrollment quotas as set forth by the study protocol.

 

Based on current and expected enrollment rates, we expect the study to be completed in 2025, depending in part by how many women are diagnosed with cervical disease. However, there can be no assurance that the study will progress and be completed within the expected timeframe, or ever.

 

Regarding international sales efforts, our focus has been on achieving regulatory approval to sell LuViva in China. Our Chinese partner, SMI, filed the application with NMPA for approval of LuViva as a Class 3 medical device in China on October 16, 2024. The results for the 449 women tested by LuViva were better than required by NMPA with a sensitivity of 83% and a specificity of 54%. There were no adverse events reported during the use of LuViva in the study, adding further evidence as to the safety of the technology. The NMPA application was accepted as complete and is under review. SMI believes NMPA approval could happen within five months, although there can be no assurance that NMPA approval will occur within the projected time frame, or ever.

 

In Europe, our distribution partners, Newmars Medical Technologies (“Newmars”), is actively pursuing potential customers in Poland, Hungary and Romania, where we have obtained the required approvals to sell our products though Newmars. In addition, an application for approval has been filed in Russia, although current geopolitics presents uncertainty as to the ability to sell and market new medical technology in that country.

 

 
38

Table of Contents

 

In Turkey, we have been in contact with three different medical groups representing over 60 individual hospitals and clinics. We have entered contract discussions for supplying LuViva to the Turkish Ministry of Health and also with a medical device distributor located in Ankara. 

 

In Indonesia, our contracted distributors are in discussions with the local government hospital system of Sulawesi, one of the nation’s most populous islands. During the fourth quarter of 2024, we received an order and full payment for four devices from Indonesia. We expect additional orders for 22 – 26 devices in 2025.  

 

CRITICAL ACCOUNTING POLICIES

 

Our material accounting policies, which we believe are the most critical to investors’ understanding of our financial results and condition, are discussed below. Because we are still early in our enterprise development, the number of these policies requiring explanation is limited. As we begin to generate increased revenue from different sources, we expect that the number of applicable policies and complexity of the judgments required will increase.

 

Revenue Recognition: ASC 606, Revenue from Contracts with Customers establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue is now recognized when control over the goods or services is transferred to the customer. The application of the core principle in ASC 606 is carried out in five steps:

 

Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled.

 

Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract.

 

Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties.

 

Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach (in limited circumstances). Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and the reallocation of changes in standalone selling prices after inception is not permitted.

 

Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date.

 

Valuation of Deferred Taxes: We account for income taxes in accordance with the liability method. Under the liability method, we recognize deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. We establish a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income.

 

 
39

Table of Contents

 

Valuation of Equity Instruments Granted to Employee, Service Providers and Investors: On the date of issuance, the instruments are recorded at their fair value as determined using the Black-Scholes or binomial lattice valuation models.

 

Allowance for Credit Losses: Trade receivables are recorded net of allowances for chargebacks, cash discounts for prompt payment and credit losses. The Company estimates an allowance for expected credit losses by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. The corresponding expense for the credit loss allowance is reflected in selling, general and administrative expenses. The allowance for credit losses was immaterial as of December 31, 2024 and 2023.

 

Inventory Valuation: All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred.

 

RESULTS OF OPERATIONS

 

COMPARISON OF THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024

 

Sales Revenue and Cost of Goods Sold: Revenues and cost of goods sold from the sale of LuViva devices and disposables for the three months ended March 31, 2025 and 2024 were not material. As of March 31, 2025, we have a deferred revenue balance of $670,305, which will be recognized as revenue when our products are shipped, which is expected to occur in 2025, upon receiving NMPA approval.

 

Research and Development Expenses: Research and development expenses were $74,122 and $53,554 during the three months ended March 31, 2025 and 2024, respectively. The increase of $20,568, or 38.4%, was primarily due to additional costs of $28,140 for sponsored research related to our clinical trials during the three months ended March 31, 2025. The increase in sponsored research costs was partially offset by a decline in patent maintenance fees of $7,658. 

 

Sales and Marketing Expenses: Sales and marketing expenses of $72,947 and $72,572 during the three months ended March 31, 2025 and 2024, respectively, were materially consistent over the two periods.

 

General and Administrative Expense: General and administrative expenses were $266,920 and $236,227 during the three months ended March 31, 2025 and 2024, respectively. The increase of $30,693, or 13.0%, was primarily driven by an increase of $32,463 in fees for professional services (including consultants) and a $4,459 increase in stock option expense. These increases were offset by a decline of $5,000 in property taxes.

 

Interest Expense: Interest expense was $146,899 and $61,473 during the three months ended March 31, 2025 and 2024, respectively. The increase of $85,426, or 139.0%, was due to an increase in debt in the current period versus the prior.

 

Change in fair value of derivative liability: The change in the fair value of our derivative liability resulted in a gain of $52,890 during the three months ended March 31, 2025. The change in the fair value was attributed to changes in our forecasted stock price and a decrease in the amount of convertible debt.

 

Gain (Loss) from Extinguishment of Debt: We recognized a loss on extinguishment of debt of $16,291 during the three months ended March 31, 2025, which was due to a loss of $31,928 for exchanges of debt for common stock and warrants, offset by a gain $15,637 for forgiveness of debt from our creditors. We recognized a gain from extinguishment of debt of $16,659 during the three months ended March 31, 2024 which was due to forgiveness of debt from our creditors.

 

Other Income: We recognized other income of $98,090 and $1,000 during the three months ended March 31, 2025 and 2024. During the three months ended March 31, 2025, we reached an agreement with SMI to apply their payment $180,000 towards reimbursement of certain expenses incurred during the years ended December 31, 2024 and 2023. As a result of this agreement, we recognized $180,000 of deferred revenue in other income. This income was offset by a $84,000 loss recorded for the write-off of a long-term asset.

 

 
40

Table of Contents

 

Preferred Stock Dividends: Expense related to preferred stock dividends of $37,559 and $38,907 for the three months ended March 31, 2025 and 2024, respectively, was materially consistent over the two periods.

 

Net Loss: Net loss attributable to common stockholders was $462,742 and $441,372 during the three months ended March 31, 2025 and 2024, respectively. The reasons for the increase in our net loss are outlined above.

 

There was no income tax benefit recorded for the three months ended March 31, 2025 or 2024, due to recurring net operating losses.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Going Concern Considerations

 

We have incurred significant losses since our inception. At March 31, 2025, the Company had negative working capital of approximately $5.1 million, accumulated deficit of $154.2 million, and incurred a net loss including preferred dividends of $0.5 million for the three months then ended. Stockholders’ deficit totaled approximately $5.0 million at March 31, 2025, primarily due to recurring net losses from operations.

 

The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.

 

Liquidity

 

Over the next 12 months we expect our burn rate to increase somewhat as we increase headcount, especially for meeting manufacturing demand. In addition, although we have significant inventory, we will need to order additional parts and services for production. Finally, we expect to spend another $300 thousand to complete and file our US FDA study. Thus, we estimate that approximately $2.5 million will be needed to fund the business over the next 12 months.  However, other than completing and filing the US FDA study results, additional expenditures for manufacturing production will be needed only if significant product is ordered and paid for in advance by customers, which is our current policy.

 

Since our inception, we have raised capital through the public and private sale of debt and equity, funding from collaborative arrangements, and grants. As of March 31, 2025, we had cash of approximately $115 thousand and negative working capital of $5.1 million. Our outstanding debt obligations include a combination of short- and long-term promissory notes, insurance premium financing, and several convertible notes with varying maturities, interest rates, and terms.

 

Promissory Notes

 

As of March 31, 2025, have a long-term note issued to a former employee in April 2024 with a remaining principal balance of $65,182, of which $24,000 is classified as short-term. This note accrues interest at 6% per annum and matures on May 5, 2028. Scheduled monthly payments of $2,000 are being made in accordance with the agreement.

 

Additionally, we entered into a premium finance agreement in July 2024 to fund insurance policies totaling $129,556. Monthly payments of $12,025 are due until the maturity of the note in May 2025. As of March 31, 2025, the outstanding balance on this financing arrangement was $23,962.

 

 
41

Table of Contents

 

Convertible Debt:

 

Our convertible debt obligations as of March 31, 2025 include the following:

 

 

·

A $1.13 million 10% Senior Unsecured Convertible Debenture, which matured on May 17, 2024, is currently in default and accruing interest at the default rate of 18%. Total accrued interest on this note was $154,810 as of March 31, 2025. The entire balance is classified as short-term convertible debt in default.

 

 

 

 

·

Two convertible notes with Diagonal Lending LLC totaling $162,150 in principal, issued in June and July 2024, have remaining balances of $30,517 as of March 31, 2025, net of $4,586 in unamortized discounts and issuance costs. These notes carry embedded conversion features that have been bifurcated and recorded as derivative liabilities. Payments on these notes are due monthly through May 2025.

 

 

 

 

·

A $200,000 convertible note issued to Flynn D. Case Living Trust, amended in December 2024, now provides for two $75,000 payments due in June and December 2025, and a final $50,000 payment in June 2026. The note includes multiple embedded conversion options with variable pricing terms, which have been bifurcated and accounted for as derivative liabilities. As of March 31, 2025, $66,634 in unamortized debt discounts remain, and $7,733 in interest has accrued.

 

 

 

 

·

A convertible note held by Auctus Fund LLC had an outstanding balance of $15,000 as of March 31, 2025. The note has accrued interest of $116,787 and is classified as short-term debt.

 

These convertible instruments, especially those with variable conversion pricing or embedded features, may result in significant dilution to existing stockholders if converted to equity. Additionally, several of the notes include default provisions or change of control clauses that may accelerate repayment obligations or increase total amounts due.

 

Related Party Debt

 

As of March 31, 2025, we also had multiple outstanding obligations to related parties, including current and former directors and executives:

 

 

·

During 2024, the Company issued $75,000 in promissory notes to members of the Board of Directors, which included 75,000 common stock warrants. As of March 31, 2025, $50,000 of these notes and $2,602 in accrued interest were exchanged for common stock and warrants. The Company recognized a $31,928 loss on extinguishment related to the exchange.

 

 

 

 

·

Dr. Mark Faupel and Dr. Gene Cartwright held promissory notes originally issued in 2018 and most recently amended in 2023 and 2025. As of March 31, 2025, Dr. Cartwright’s $0.3 million note was overdue, while Dr. Faupel’s $0.2 million note was extended to mature in February 2026.

 

 

 

 

·

A note issued to Richard Fowler in 2021 had a remaining principal balance of $33,753 as of March 31, 2025. The note carries a 6% interest rate and is being repaid in monthly installments. Mr. Fowler has forgiven portions of the deferred compensation related to this note, which was accounted for as a troubled debt restructuring.

 

Summary of our Cash Flows

 

Our major cash flows for the three months ended March 31, 2025 consisted of cash used for operating activities of $331 thousand, proceeds from the issuance of common stock and warrants of $205 thousand and payments of debt of $147 thousand.

 

Our major cash flows for the three months ended March 31, 2024 consisted of cash used for operating activities of $100 thousand and payments of debt of $46 thousand.

 

The increase in cash used in operating activities was primarily attributable to the timing of payments associated with our accounts payable and accrued liabilities and a $179 thousand decrease to deferred revenue in the current period. The $104 thousand increase in cash provided by financing activities was attributed to $205 thousand of proceeds from the issuance of common stock and warrants in a private placement offering during the three months ended March 31, 2025. The increase was offset by an $101 thousand increase in debt payments during the three months ended March 31, 2025 versus the three months ended March 31, 2024.

 

Off-Balance Sheet Arrangements

 

We have no material off-balance sheet arrangements, no special purpose entities, and no activities that include non-exchange-traded contracts accounted for at fair value.

 

 
42

Table of Contents

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company, we are not required to provide the information required by this item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

We maintain a set of disclosure controls and procedures designed to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported, within the time periods specified in Securities and Exchange Commission (“Commission”) rules and forms. We carried out an evaluation under the supervision and with the participation of our management, including the Chief Executive Officer/Acting Chief Financial Officer, Mark Faupel, of the effectiveness of its disclosure controls and procedures. Based on that evaluation, the Chief Executive Officer/Acting Chief Financial Officer has concluded that our disclosure controls and procedures were ineffective as of March 31, 2025, due to the existence of material weaknesses in our internal control over financial reporting. The material weaknesses identified arose from a lack of recourses to properly research and account for complex transactions and lack of oversight and approval by the Board of Directors and Audit Committee, including formally documented approval of significant transactions, including related party transactions. While management is currently in the early stages of developing a remediation plan, we have yet to fully remediate this material weakness.

 

Changes in Internal Control Over Financial Reporting

 

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 
43

Table of Contents

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the disposition of these matters, individually or in the aggregate, is not expected to have a material adverse effect on the Company’s financial condition.

 

ITEM 1A. RISK FACTORS

 

There have been no material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K as filed with the SEC on March 31, 2025.

 

ITEM 2. UNREGISTERRED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

On March 18, 2025, the Company entered into a Securities Purchase Agreement (the “March Purchase Agreement”) with certain institutional investors, including John Imhoff and Michael James, members of the Company’s Board of Directors, for the purpose of raising $257,102 in gross proceeds for the Company. Pursuant to the terms of the March Purchase Agreement, the Company agreed to sell, in a private placement offering, an aggregate of 2,571,023 units, each unit consisting of one share of common stock and one warrant to purchase up to 2,571,023 shares of common stock (the “March Warrants”). The purchase price per unit was $0.10. The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share.

 

The Company intends to use the net proceeds from the transactions for general corporate purposes and working capital, including manufacturing expenses for filling product orders placed recently by international distribution partners.

 

ITEM 3: DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4: MINE SAFETY DISCLOSURES.

 

Not applicable

 

ITEM 5: OTHER INFORMATION.

 

None.

 

 
44

Table of Contents

 

ITEM 6. EXHIBITS

 

Exhibit Number

 

Exhibit Description

 

 

 

3.1

 

Restated Certificate of Incorporation, as amended through November 3, 2016 (incorporated by reference to Exhibit 3.1 to the annual report on Form 10-K filed March 15, 2016)

3.2

 

Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed March 23, 2012)

3.3

 

Amended and Restated Certificate of Incorporation, (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed November 15, 2018)

3.4

 

Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020)

3.5

 

Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.5 to the annual report on Form 10-K filed April 5, 2021)

3.6

 

Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock (incorporated by reference to Exhibit 3.6 to the annual report on Form 10-K filed April 5, 2021)

3.7

 

Certificate of Designation of Preferences, Rights and Limitations of Series F-2 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on June 10, 2021)

3.8

 

Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock (incorporated by reference to Exhibit 3.8 to the annual report on Form 10-K filed March 30, 2022)

3.9

 

Certificate of Amendment to the Certificate of Incorporation of Guided Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on January 7, 2022)

10.1

 

Form of Convertible Promissory Note Dated May 2, 2025

10.2

 

Form of Warrant Dated May 2, 2025

10.3

 

Form of Promissory Note Dated April 1, 2025

10.4

 

Form of Securities Purchase Agreement Dated April 1, 2025

10.5

 

Form of Promissory Note Dated May 1, 2025

10.6

 

Form of Securities Purchase Agreement Dated May 1, 2025

31*

 

Rule 13a-14(a)/15d-14(a) Certification

32*

 

Section 1350 Certification

101.1*

 

Interactive data files for Guided Therapeutics, Inc. 's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in Inline XBRL: (i) the Condensed Consolidated Balance Sheets (unaudited); (ii) the Condensed Consolidated Statements of Income (unaudited);  (iii) the Condensed Consolidated Statements in Stockholders' Deficit (unaudited); (iv) the Condensed Consolidated Statements of Cash Flows (unaudited); and (v) the Notes to the Condensed Consolidated Financial Statements (unaudited).

104

 

The cover page from Guided Therapeutics, Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (formatted in Inline XBRL and included in Exhibit 101)

______________     

*Filed herewith    

 

 
45

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

GUIDED THERAPEUTICS, INC.

 

By:

/s/ Mark Faupel

Mark Faupel

President, Chief Executive Officer, Chief Operating Officer and Acting Chief Financial Officer

 

Date: May 15, 2025

 

 
46